[S02DA03, antipyrine, The protein binding of Valproic acid can be decreased when combined with Antipyrine.]
[G03XB02, ulipristal, The metabolism of Ulipristal can be increased when combined with Valproic acid.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Valproic acid.]
[J01EC02, sulfadiazine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Sulfadiazine.]
[S01AB01, sulfamethizole, The metabolism of Valproic acid can be decreased when combined with Sulfamethizole.]
[J01EC01, sulfamethoxazole, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Valproic acid.]
[J01EC03, sulfamoxole, The metabolism of Valproic acid can be decreased when combined with Sulfamoxole.]
[J01EB04, sulfapyridine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Sulfapyridine.]
[M04AB02, sulfinpyrazone, The metabolism of Valproic acid can be decreased when combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Valproic acid.]
[M01AB02, sulindac, The protein binding of Valproic acid can be decreased when combined with Sulindac.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Valproic acid.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Valproic acid is combined with Sulthiame.]
[M01AE07, suprofen, The protein binding of Valproic acid can be decreased when combined with Suprofen.]
[A10BB04, glibornuride, The metabolism of Glibornuride can be decreased when combined with Valproic acid.]
[M01AX04, apazone, The protein binding of Valproic acid can be decreased when combined with Azapropazone.]
[L01BB02, mercaptopurine, The excretion of Mercaptopurine can be decreased when combined with Valproic acid.]
[N06DA01, tacrine, The metabolism of Tacrine can be decreased when combined with Valproic acid.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Valproic acid.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Valproic acid.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Valproic acid.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Valproic acid.]
[G03BA03, testosterone, The excretion of Valproic acid can be increased when combined with Testosterone.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Tetracaine.]
[S03AA02, tetracycline, The excretion of Valproic acid can be decreased when combined with Tetracycline.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Valproic acid.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Valproic acid.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Valproic acid.]
[L04AX02, thalidomide, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, Valproic acid may increase the excretion rate of Theobromine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Valproic acid.]
[P02CA02, thiabendazole, The metabolism of Thiabendazole can be decreased when combined with Valproic acid.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Eribulin is combined with Valproic acid.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Thiethylperazine.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be decreased when combined with Valproic acid.]
[N05CA19, thiopental, The serum concentration of Thiopental can be increased when it is combined with Valproic acid.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Thioproperazine.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Valproic acid.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Valproic acid is combined with Tiapride.]
[B01AC05, ticlopidine, The metabolism of Valproic acid can be decreased when combined with Ticlopidine.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Tilidine.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Timolol is combined with Valproic acid.]
[A10BB05, tolazamide, The metabolism of Tolazamide can be decreased when combined with Valproic acid.]
[V04CA01, tolbutamide, The metabolism of Tolbutamide can be decreased when combined with Valproic acid.]
[M02AA21, tolmetin, The protein binding of Valproic acid can be decreased when combined with Tolmetin.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Tramadol.]
[N06AF04, tranylcypromine, The metabolism of Valproic acid can be decreased when combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Valproic acid.]
[L01XF01, tretinoin, Valproic acid may increase the Pseudotumor Cerebri activities of Tretinoin.]
[C03DB02, triamterene, The metabolism of Triamterene can be decreased when combined with Valproic acid.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Triazolam.]
[A03AB12, mepenzolate, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Trifluoperazine.]
[S01AD02, trifluridine, The excretion of Trifluridine can be decreased when combined with Valproic acid.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Valproic acid is combined with Trifluperidol.]
[N05AA05, triflupromazine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[N04AA01, trihexyphenidyl, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[A03AA05, trimebutine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Valproic acid.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Valproic acid.]
[J01EA01, trimethoprim, The metabolism of Trimethoprim can be decreased when combined with Valproic acid.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Valproic acid.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Valproic acid.]
[A03BB01, butylscopolamine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[N06AX24, vilazodone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Valproic acid.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Tubocurarine.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Valproic acid.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be decreased when combined with Valproic acid.]
[A10BH05, linagliptin, The metabolism of Linagliptin can be decreased when combined with Valproic acid.]
[J05AG05, rilpivirine, The metabolism of Valproic acid can be decreased when combined with Rilpivirine.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Valproic acid.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Valproic acid.]
[B01AC24, ticagrelor, The metabolism of Valproic acid can be decreased when combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Verapamil can be decreased when combined with Valproic acid.]
[N06AX09, viloxazine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be decreased when combined with Valproic acid.]
[L01CA02, vincristine, The metabolism of Vincristine can be decreased when combined with Valproic acid.]
[L01CA03, vindesine, The metabolism of Vindesine can be decreased when combined with Valproic acid.]
[S01XA02, vitamin A, Valproic acid may increase the Pseudotumor Cerebri activities of Vitamin A.]
[B01AA03, warfarin, The serum concentration of Warfarin can be increased when it is combined with Valproic acid.]
[S01AA13, fusidic acid, The metabolism of Fusidic acid can be decreased when combined with Valproic acid.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Valproic acid.]
[J05AF01, zidovudine, The serum concentration of Zidovudine can be increased when it is combined with Valproic acid.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Valproic acid can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Levetiracetam.]
[L01EC01, vemurafenib, The metabolism of Vemurafenib can be decreased when combined with Valproic acid.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be decreased when combined with Valproic acid.]
[L01ED01, crizotinib, The metabolism of Crizotinib can be decreased when combined with Valproic acid.]
[R03DC01, zafirlukast, The metabolism of Valproic acid can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, The metabolism of Rabeprazole can be decreased when combined with Valproic acid.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Valproic acid.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Drospirenone can be increased when combined with Valproic acid.]
[N02BA01, aspirin, The metabolism of Valproic acid can be decreased when combined with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be decreased when combined with Valproic acid.]
[G04BD07, tolterodine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[J01DH04, doripenem, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Doripenem.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Valproic acid.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Valproic acid is combined with Atracurium.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Atropine is combined with Valproic acid.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Valproic acid.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Valproic acid.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Valproic acid.]
[L04AX01, azathioprine, The metabolism of Azathioprine can be decreased when combined with Valproic acid.]
[J01CA09, azlocillin, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Azlocillin.]
[G04BE10, avanafil, The metabolism of Avanafil can be decreased when combined with Valproic acid.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Valproic acid.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Valproic acid is combined with Lorcaserin.]
[G04BD12, mirabegron, The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Valproic acid.]
[J05AJ02, elvitegravir, The metabolism of Elvitegravir can be decreased when combined with Valproic acid.]
[L02BB04, enzalutamide, The serum concentration of Valproic acid can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be decreased when combined with Valproic acid.]
[L04AA31, teriflunomide, The excretion of Valproic acid can be decreased when combined with Teriflunomide.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be decreased when combined with Valproic acid.]
[N05CA04, barbital, The serum concentration of Barbital can be increased when it is combined with Valproic acid.]
[J05AE04, nelfinavir, The metabolism of Valproic acid can be increased when combined with Nelfinavir.]
[L01AA09, bendamustine, The metabolism of Bendamustine can be decreased when combined with Valproic acid.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Valproic acid.]
[N04BD02, rasagiline, The risk or severity of adverse effects can be increased when Valproic acid is combined with Rasagiline.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Valproic acid is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Valproic acid is combined with Donepezil.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Valproic acid.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Valproic acid.]
[N02CC03, zolmitriptan, The metabolism of Zolmitriptan can be decreased when combined with Valproic acid.]
[R06AC06, thonzylamine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Valproic acid is combined with Diethyl ether.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Valproic acid.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Valproic acid.]
[G04BE03, sildenafil, The metabolism of Sildenafil can be decreased when combined with Valproic acid.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Valproic acid.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Valproic acid.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be decreased when combined with Valproic acid.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Valproic acid.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Bencyclane is combined with Valproic acid.]
[A16AX09, glycerol phenylbutyrate, The therapeutic efficacy of Glycerol phenylbutyrate can be decreased when used in combination with Valproic acid.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be decreased when combined with Valproic acid.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Valproic acid.]
[N02BA10, benorilate, The protein binding of Valproic acid can be decreased when combined with Benorilate.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Valproic acid is combined with Benperidol.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Valproic acid.]
[M04AB03, benzbromarone, The metabolism of Valproic acid can be decreased when combined with Benzbromarone.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Valproic acid.]
[A06AX06, tegaserod, The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Tegaserod.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Benzocaine.]
[M01AH01, celecoxib, The protein binding of Valproic acid can be decreased when combined with Celecoxib.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Valproic acid is combined with Naratriptan.]
[L04AA18, everolimus, The metabolism of Everolimus can be decreased when combined with Valproic acid.]
[N04AC01, benztropine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Valproic acid can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The protein binding of Valproic acid can be decreased when combined with Benzydamine.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Valproic acid is combined with Levomilnacipran.]
[J05AJ03, dolutegravir, The excretion of Valproic acid can be decreased when combined with Dolutegravir.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Bepridil.]
[A05AA03, cholic acid, The excretion of Valproic acid can be decreased when combined with Cholic Acid.]
[G03XC02, bazedoxifene, The metabolism of Bazedoxifene can be decreased when combined with Valproic acid.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Valproic acid.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Vortioxetine.]
[G03AC08, etonogestrel, The metabolism of Etonogestrel can be increased when combined with Valproic acid.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Eslicarbazepine.]
[D01AC18, luliconazole, The serum concentration of Valproic acid can be increased when it is combined with Luliconazole.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Valproic acid is combined with Vigabatrin.]
[A10BK01, dapagliflozin, The metabolism of Dapagliflozin can be decreased when combined with Valproic acid.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Valproic acid is combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Valproic acid can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Valproic acid can be increased when combined with Apremilast.]
[S03BA03, betamethasone, The metabolism of Valproic acid can be increased when combined with Betamethasone.]
[S01ED02, betaxolol, The metabolism of Betaxolol can be decreased when combined with Valproic acid.]
[V03AB34, fomepizole, The metabolism of Valproic acid can be decreased when combined with Fomepizole.]
[L04AC11, siltuximab, The metabolism of Valproic acid can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Ceritinib can be decreased when combined with Valproic acid.]
[B01AC26, vorapaxar, The metabolism of Vorapaxar can be decreased when combined with Valproic acid.]
[A03BA03, hyoscyamine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be increased when it is combined with Valproic acid.]
[L01XH04, belinostat, The metabolism of Belinostat can be decreased when combined with Valproic acid.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be decreased when combined with Valproic acid.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Alfaxalone.]
[N07XX08, tafamidis, The excretion of Valproic acid can be decreased when combined with Tafamidis.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Valproic acid.]
[D11AA01, glycopyrronium, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Valproic acid.]
[J01XA05, oritavancin, The metabolism of Valproic acid can be decreased when combined with Oritavancin.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Acepromazine.]
[N04AA02, biperiden, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Valproic acid.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be decreased when combined with Valproic acid.]
[J05AP09, dasabuvir, The metabolism of Valproic acid can be decreased when combined with Dasabuvir.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Valproic acid.]
[B01AA01, dicumarol, The metabolism of Dicoumarol can be decreased when combined with Valproic acid.]
[N06AX11, mirtazapine, Valproic acid may increase the serotonergic activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Valproic acid can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be decreased when combined with Valproic acid.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Valproic acid.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be decreased when combined with Valproic acid.]
[N02BE01, acetaminophen, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Acetaminophen.]
[L01DC01, bleomycin, The serum concentration of Valproic acid can be decreased when it is combined with Bleomycin.]
[A03AA09, difemerine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Ivabradine.]
[J05AF08, adefovir dipivoxil, The excretion of Adefovir dipivoxil can be decreased when combined with Valproic acid.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be decreased when combined with Valproic acid.]
[A07DA06, eluxadoline, The excretion of Eluxadoline can be decreased when combined with Valproic acid.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Valproic acid is combined with Brexpiprazole.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be decreased when combined with Valproic acid.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Valproic acid is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Cariprazine.]
[M02AA25, aceclofenac, The protein binding of Valproic acid can be decreased when combined with Aceclofenac.]
[M01AB11, acemetacin, The protein binding of Valproic acid can be decreased when combined with Acemetacin.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Acetazolamide.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Acetophenazine.]
[D05BB02, acitretin, Valproic acid may increase the Pseudotumor Cerebri activities of Acitretin.]
[A02BC03, lansoprazole, The metabolism of Valproic acid can be decreased when combined with Lansoprazole.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Valproic acid.]
[J02AC05, isavuconazole, The metabolism of Valproic acid can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be decreased when combined with Valproic acid.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Valproic acid.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be decreased when combined with Valproic acid.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be decreased when combined with Valproic acid.]
[L01ED03, alectinib, The metabolism of Alectinib can be decreased when combined with Valproic acid.]
[A10BB31, acetohexamide, The metabolism of Acetohexamide can be decreased when combined with Valproic acid.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Valproic acid.]
[M04AB05, lesinurad, The metabolism of Lesinurad can be decreased when combined with Valproic acid.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Valproic acid is combined with Aprobarbital.]
[M01AE16, alminoprofen, The protein binding of Valproic acid can be decreased when combined with Alminoprofen.]
[N02BA02, aloxiprin, The serum concentration of Valproic acid can be increased when it is combined with Aloxiprin.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Brivaracetam.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be decreased when combined with Valproic acid.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Bromazepam.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Bromocriptine.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Alverine.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Valproic acid.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Valproic acid is combined with Amineptine.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be decreased when combined with Valproic acid.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Aniracetam.]
[M02AA09, bufexamac, The protein binding of Valproic acid can be decreased when combined with Bufexamac.]
[C03CA02, bumetanide, The excretion of Valproic acid can be decreased when combined with Bumetanide.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Bupivacaine.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Bupranolol is combined with Valproic acid.]
[N07BC01, buprenorphine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Valproic acid.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Buspirone.]
[L01AB01, busulfan, The metabolism of Busulfan can be decreased when combined with Valproic acid.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Artemether.]
[M02AA03, clofezone, The metabolism of Rabeprazole can be decreased when combined with Valproic acid.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Valproic acid is combined with Butorphanol.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Valproic acid.]
[S01GX07, azelastine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Valproic acid can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Valproic acid.]
[L01EF02, ribociclib, The metabolism of Ribociclib can be decreased when combined with Valproic acid.]
[A07EC04, balsalazide, The serum concentration of Valproic acid can be increased when it is combined with Balsalazide.]
[R03DA08, bamifylline, Valproic acid may increase the excretion rate of Bamifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Deutetrabenazine.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Beclamide.]
[N06BC01, caffeine, Valproic acid may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Oxybuprocaine.]
[J01XX08, linezolid, The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Valproic acid.]
[J05AF06, abacavir, The metabolism of Abacavir can be decreased when combined with Valproic acid.]
[J05AE09, tipranavir, The metabolism of Valproic acid can be increased when combined with Tipranavir.]
[L04AB02, infliximab, The metabolism of Valproic acid can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Midostaurin can be decreased when combined with Valproic acid.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Valproic acid.]
[N04BD03, safinamide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Safinamide.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Valproic acid.]
[L01BC06, capecitabine, The metabolism of Capecitabine can be decreased when combined with Valproic acid.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Valproic acid.]
[L01EH02, neratinib, The metabolism of Neratinib can be decreased when combined with Valproic acid.]
[L01XH01, vorinostat, The risk or severity of gastrointestinal bleeding and thrombocytopenia can be increased when Valproic acid is combined with Vorinostat.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Valproic acid.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be decreased when combined with Valproic acid.]
[J05AG03, efavirenz, The metabolism of Valproic acid can be increased when combined with Efavirenz.]
[N04AA11, bornaprine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[S01BC11, bromfenac, The protein binding of Valproic acid can be decreased when combined with Bromfenac.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Valproic acid is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Brotizolam.]
[M01AB07, bumadizone, The protein binding of Valproic acid can be decreased when combined with Bumadizone.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be decreased when combined with Valproic acid.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Valproic acid is combined with Butobarbital.]
[J05AX18, letermovir, The excretion of Valproic acid can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Valproic acid.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Valproic acid.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Capsaicin.]
[A10BK04, ertugliflozin, The metabolism of Valproic acid can be decreased when combined with Ertugliflozin.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Valproic acid is combined with Vinylbital.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Valproic acid.]
[C09AA01, captopril, The excretion of Captopril can be decreased when combined with Valproic acid.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Macimorelin.]
[L02BB05, apalutamide, The serum concentration of Valproic acid can be increased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The serum concentration of carbamazepine-10,11­ epoxide (CBZ-E), an active metabolite of Carbamazepine, can be increased when used in combination with Valproic acid.]
[A03AA03, camylofine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Valproic acid.]
[C07AG02, carvedilol, The metabolism of Carvedilol can be decreased when combined with Valproic acid.]
[B02BX09, fostamatinib, The metabolism of Valproic acid can be decreased when combined with Fostamatinib.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Valproic acid.]
[B02BX08, avatrombopag, The excretion of Valproic acid can be decreased when combined with Avatrombopag.]
[L04AA37, baricitinib, The serum concentration of Baricitinib can be increased when it is combined with Valproic acid.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Valproic acid.]
[L01EE03, binimetinib, The metabolism of Binimetinib can be decreased when combined with Valproic acid.]
[J01DD14, ceftibuten, The excretion of Valproic acid can be decreased when combined with Ceftibuten.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Valproic acid.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Valproic acid.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Ivosidenib.]
[A16AX14, migalastat, The metabolism of Migalastat can be decreased when combined with Valproic acid.]
[N03AX17, stiripentol, The metabolism of Valproic acid can be decreased when combined with Stiripentol.]
[J05AX24, tecovirimat, The metabolism of Valproic acid can be decreased when combined with Tecovirimat.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be decreased when combined with Valproic acid.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Valproic acid.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Valproic acid.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Valproic acid is combined with Carbromal.]
[A10BB06, carbutamide, The metabolism of Carbutamide can be decreased when combined with Valproic acid.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Chloroprocaine.]
[R06AA06, chlorphenoxamine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The protein binding of Valproic acid can be decreased when combined with Lornoxicam.]
[R03DA02, oxtriphylline, Valproic acid may increase the excretion rate of Oxtriphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Inotersen is combined with Valproic acid.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Valproic acid.]
[R03BB08, revefenacin, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L04AA39, emapalumab, The metabolism of Valproic acid can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The metabolism of Carmustine can be decreased when combined with Valproic acid.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Valproic acid.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Valproic acid.]
[A06AX05, prucalopride, The metabolism of Prucalopride can be decreased when combined with Valproic acid.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Valproic acid.]
[B01AC23, cilostazol, The serum concentration of Cilostazol can be increased when it is combined with Valproic acid.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Valproic acid is combined with Cinitapride.]
[P02BX04, triclabendazole, The metabolism of Valproic acid can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Esketamine.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Valproic acid is combined with Siponimod.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation can be increased when Clarithromycin is combined with Valproic acid.]
[N06BA14, solriamfetol, The risk or severity of adverse effects can be increased when Valproic acid is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Brexanolone.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Valproic acid.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Clobazam.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Cloxazolam.]
[C09CA06, candesartan, The metabolism of Candesartan can be decreased when combined with Valproic acid.]
[L04AB01, etanercept, The metabolism of Valproic acid can be increased when combined with Etanercept.]
[L01EM03, alpelisib, The serum concentration of Valproic acid can be decreased when it is combined with Alpelisib.]
[J01DC04, cefaclor, The excretion of Valproic acid can be decreased when combined with Cefaclor.]
[J01DB05, cefadroxil, The excretion of Valproic acid can be decreased when combined with Cefadroxil.]
[J01DC03, cefamandole, The excretion of Valproic acid can be decreased when combined with Cefamandole.]
[J01DB04, cefazolin, The excretion of Valproic acid can be decreased when combined with Cefazolin.]
[L02BB06, darolutamide, The metabolism of Darolutamide can be decreased when combined with Valproic acid.]
[L01EX15, pexidartinib, Valproic acid may increase the hepatotoxic activities of Pexidartinib.]
[J01DD12, cefoperazone, The excretion of Valproic acid can be decreased when combined with Cefoperazone.]
[J01DD01, cefotaxime, The excretion of Valproic acid can be decreased when combined with Cefotaxime.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Cyamemazine.]
[J01DC07, cefotiam, The excretion of Valproic acid can be decreased when combined with Cefotiam.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Cicletanine is combined with Valproic acid.]
[J01DD07, ceftizoxime, The excretion of Valproic acid can be decreased when combined with Ceftizoxime.]
[J01DD04, ceftriaxone, The excretion of Valproic acid can be decreased when combined with Ceftriaxone.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Valproic acid.]
[L01EJ02, fedratinib, The metabolism of Fedratinib can be decreased when combined with Valproic acid.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Entrectinib.]
[N07XX11, pitolisant, Valproic acid may increase the QTc-prolonging activities of Pitolisant.]
[J04AK08, pretomanid, The metabolism of Pretomanid can be decreased when combined with Valproic acid.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Valproic acid.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Valproic acid.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Yohimbine.]
[J01DB01, cephalexin, The excretion of Valproic acid can be decreased when combined with Cephalexin.]
[J01DB02, cephaloridine, The excretion of Valproic acid can be decreased when combined with Cefaloridine.]
[J01DB03, cephalothin, The excretion of Valproic acid can be decreased when combined with Cefalotin.]
[G03DB05, demegestone, The metabolism of Demegestone can be increased when combined with Valproic acid.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Valproic acid.]
[N02CC08, lasmiditan, The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Valproic acid.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Valproic acid.]
[G03AC09, desogestrel, The metabolism of Desogestrel can be increased when combined with Valproic acid.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be increased when it is combined with Valproic acid.]
[N03AX25, cenobamate, The serum concentration of Valproic acid can be decreased when it is combined with Cenobamate.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Valproic acid.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Valproic acid.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Dezocine.]
[L01EX18, avapritinib, The metabolism of Avapritinib can be decreased when combined with Valproic acid.]
[N05CM21, lemborexant, The serum concentration of Valproic acid can be decreased when it is combined with Lemborexant.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be decreased when combined with Valproic acid.]
[N05AD10, lumateperone, The serum concentration of Lumateperone can be increased when it is combined with Valproic acid.]
[M01AX21, diacetylrhein, The metabolism of Valproic acid can be decreased when combined with Diacerein.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Valproic acid.]
[H02CA02, osilodrostat, The metabolism of Valproic acid can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Amprenavir can be decreased when combined with Valproic acid.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Valproic acid is combined with Frovatriptan.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Dichloralphenazone.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Valproic acid.]
[G03DB08, dienogest, The metabolism of Dienogest can be increased when combined with Valproic acid.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Valproic acid is combined with Difenoxin.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Valproic acid.]
[M01AH02, rofecoxib, The protein binding of Valproic acid can be decreased when combined with Rofecoxib.]
[L01XF03, bexarotene, Valproic acid may increase the Pseudotumor Cerebri activities of Bexarotene.]
[C08CA16, clevidipine, The metabolism of Valproic acid can be decreased when combined with Clevidipine.]
[C01BD07, dronedarone, Valproic acid may increase the QTc-prolonging activities of Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Valpromide.]
[L01AA02, chlorambucil, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Chlorambucil.]
[S03AA08, chloramphenicol, The metabolism of Valproic acid can be decreased when combined with Chloramphenicol.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Valproic acid.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Chlordiazepoxide.]
[L01FX17, sacituzumab govitecan, The serum concentration of Sacituzumab govitecan can be increased when it is combined with Valproic acid.]
[A03AA08, dihexyverine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[P01BE01, artemisinin, The metabolism of Artemisinin can be decreased when combined with Valproic acid.]
[G04BD09, trospium, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, The protein binding of Valproic acid can be decreased when combined with Droxicam.]
[M02AA27, dexketoprofen, The protein binding of Valproic acid can be decreased when combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Valproic acid is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Chlormezanone.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Dyclonine.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Valproic acid.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Ebastine is combined with Valproic acid.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Valproic acid.]
[P01BB01, proguanil, The metabolism of Proguanil can be decreased when combined with Valproic acid.]
[N05CD14, remimazolam, The risk or severity of sedation can be increased when Valproic acid is combined with Remimazolam.]
[N07XX04, sodium oxybate, The serum concentration of Sodium oxybate can be increased when it is combined with Valproic acid.]
[L04AC19, satralizumab, The serum concentration of Valproic acid can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Valproic acid is combined with Oliceridine.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Valproic acid.]
[L01EX23, pralsetinib, The metabolism of Valproic acid can be decreased when combined with Pralsetinib.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Valproic acid.]
[N05AA01, chlorpromazine, The serum concentration of Valproic acid can be increased when it is combined with Chlorpromazine.]
[A10BB02, chlorpropamide, The metabolism of Chlorpropamide can be decreased when combined with Valproic acid.]
[N05AF03, chlorprothixene, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Chlorzoxazone.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Etifoxine.]
[N02BA07, ethenzamide, The protein binding of Valproic acid can be decreased when combined with Ethenzamide.]
[N02BA03, choline salicylate, The serum concentration of Valproic acid can be increased when it is combined with Choline salicylate.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Valproic acid is combined with Ethyl loflazepate.]
[G03DC06, ethynodiol, The metabolism of Etynodiol can be increased when combined with Valproic acid.]
[M01AB08, etodolac, The protein binding of Valproic acid can be decreased when combined with Etodolac.]
[M02AA06, etofenamate, The protein binding of Valproic acid can be decreased when combined with Etofenamate.]
[B06AC06, berotralstat, The risk or severity of QTc prolongation can be increased when Berotralstat is combined with Valproic acid.]
[A16AX20, lonafarnib, The metabolism of Lonafarnib can be decreased when combined with Valproic acid.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Valproic acid.]
[J05AJ04, cabotegravir, The excretion of Valproic acid can be decreased when combined with Cabotegravir.]
[P03AX07, abametapir, The serum concentration of Valproic acid can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The metabolism of Valproic acid can be decreased when combined with Tepotinib.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Valproic acid is combined with Febarbamate.]
[N03AX10, felbamate, The serum concentration of Valproic acid can be increased when it is combined with Felbamate.]
[M01AE05, fenbufen, The protein binding of Valproic acid can be decreased when combined with Fenbufen.]
[N06BA10, fenethylline, Valproic acid may increase the excretion rate of Fenethylline which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD15, cefdinir, The excretion of Cefdinir can be decreased when combined with Valproic acid.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Flumequine is combined with Valproic acid.]
[S01JA01, fluorescein, The excretion of Fluorescein can be decreased when combined with Valproic acid.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Valproic acid.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Valproic acid.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Valproic acid is combined with Trichloroethylene.]
[L03AB10, peginterferon alfa-2b, The metabolism of Valproic acid can be increased when combined with Peginterferon alfa-2b.]
[A02BA01, cimetidine, The excretion of Valproic acid can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Valproic acid is combined with Gabapentin.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Valproic acid.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Valproic acid.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be decreased when combined with Valproic acid.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Valproic acid.]
[L01XA01, cisplatin, The metabolism of Valproic acid can be decreased when combined with Cisplatin.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Citalopram.]
[H01AC07, somapacitan, The metabolism of Valproic acid can be decreased when combined with Somapacitan.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Valproic acid.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Valproic acid is combined with Fexinidazole.]
[L01XX74, belzutifan, The serum concentration of Belzutifan can be increased when it is combined with Valproic acid.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Mobocertinib.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Clemastine is combined with Valproic acid.]
[M01AG01, mefenamic acid, The protein binding of Valproic acid can be decreased when combined with Mefenamic acid.]
[A10BB12, glimepiride, The metabolism of Glimepiride can be decreased when combined with Valproic acid.]
[A10BB08, gliquidone, The metabolism of Gliquidone can be decreased when combined with Valproic acid.]
[N06AX25, St. John's wort extract, The risk or severity of adverse effects can be increased when Valproic acid is combined with St. John's Wort.]
[L01EA06, asciminib, The metabolism of Valproic acid can be decreased when combined with Asciminib.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Valproic acid.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Valproic acid.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Valproic acid.]
[C10AB01, clofibrate, The metabolism of Valproic acid can be decreased when combined with Clofibrate.]
[B06AX04, mitapivat, The metabolism of Valproic acid can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Pacritinib is combined with Valproic acid.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Valproic acid.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Clonazepam.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Valproic acid.]
[C01EB24, mavacamten, The serum concentration of Mavacamten can be increased when it is combined with Valproic acid.]
[J05AH02, oseltamivir, The excretion of Oseltamivir can be decreased when combined with Valproic acid.]
[A02BC08, vonoprazan, The metabolism of Valproic acid can be decreased when combined with Vonoprazan.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Clotiazepam.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Valproic acid.]
[M02AA08, felbinac, The protein binding of Valproic acid can be decreased when combined with Felbinac.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Granisetron is combined with Valproic acid.]
[N05AH02, clozapine, The risk or severity of QTc prolongation can be increased when Clozapine is combined with Valproic acid.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Halazepam.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Cocaine.]
[M09AX11, palovarotene, Valproic acid may increase the Pseudotumor Cerebri activities of Palovarotene.]
[C02KB01, metyrosine, Valproic acid may increase the sedative activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Valproic acid can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The protein binding of Valproic acid can be decreased when combined with Proquazone.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Codeine.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Valproic acid is combined with Hexafluronium.]
[M04AC01, colchicine, The metabolism of Colchicine can be decreased when combined with Valproic acid.]
[A03AB10, hexocyclium, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[L04AA13, leflunomide, The metabolism of Leflunomide can be decreased when combined with Valproic acid.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Valproic acid.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Valproic acid is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Valproic acid is combined with Ifenprodil.]
[A10BX03, nateglinide, The metabolism of Nateglinide can be decreased when combined with Valproic acid.]
[N02BA16, imidazole-2-hydroxybenzoate, The protein binding of Valproic acid can be decreased when combined with Imidazole salicylate.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Telithromycin is combined with Valproic acid.]
[B01AC10, indobufen, The protein binding of Valproic acid can be decreased when combined with Indobufen.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Valproic acid.]
[J05AB14, valganciclovir, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Valganciclovir.]
[M01AH03, valdecoxib, The protein binding of Valproic acid can be decreased when combined with Valdecoxib.]
[A03AX10, isometheptene, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Isometheptene.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Valproic acid is combined with Almotriptan.]
[M01AH04, parecoxib, The protein binding of Valproic acid can be decreased when combined with Parecoxib.]
[J02AC02, itraconazole, The metabolism of Valproic acid can be decreased when combined with Itraconazole.]
[S01AD03, acyclovir, The excretion of Valproic acid can be decreased when combined with Acyclovir.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Emedastine is combined with Valproic acid.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Ketazolam.]
[M01AA06, kebuzone, The protein binding of Valproic acid can be decreased when combined with Kebuzone.]
[L02BA03, fulvestrant, The metabolism of Fulvestrant can be decreased when combined with Valproic acid.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Imatinib.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Valproic acid.]
[A02BC05, esomeprazole, The excretion of Valproic acid can be decreased when combined with Esomeprazole.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Valproic acid.]
[V03AF07, rasburicase, The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Valproic acid.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Valproic acid.]
[N03AX09, lamotrigine, Valproic acid may decrease the excretion rate of Lamotrigine which could result in a higher serum level.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Valproic acid.]
[N07BC04, lofexidine, The therapeutic efficacy of Valproic acid can be increased when used in combination with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Valproic acid.]
[M01AB09, lonazolac, The protein binding of Valproic acid can be decreased when combined with Lonazolac.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Lormetazepam.]
[H01AA02, cosyntropin, Tetracosactide may increase the hepatotoxic activities of Valproic acid.]
[M02AA31, loxoprofen, The protein binding of Valproic acid can be decreased when combined with Loxoprofen.]
[C08CA11, manidipine, The metabolism of Valproic acid can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Medifoxamine.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Valproic acid.]
[J01DH02, meropenem, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Meropenem.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Valproic acid.]
[R06AD04, methdilazine, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Methdilazine.]
[N04AA03, methixene, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[R03CB02, methoxyphenamine, The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Valproic acid.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Valproic acid is combined with Cyclobarbital.]
[S01BC10, nepafenac, The protein binding of Valproic acid can be decreased when combined with Nepafenac.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Melperone is combined with Valproic acid.]
[J05AF07, tenofovir disoproxil, The excretion of Tenofovir disoproxil can be decreased when combined with Valproic acid.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Valproic acid.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Minaprine.]
[S01XA18, cyclosporine, The metabolism of Cyclosporine can be decreased when combined with Valproic acid.]
[N06AG02, moclobemide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Moclobemide.]
[N06BA07, modafinil, The metabolism of Valproic acid can be decreased when combined with Armodafinil.]
[R06AX02, cyproheptadine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Valproic acid.]
[C10AA07, rosuvastatin, The excretion of Valproic acid can be decreased when combined with Rosuvastatin.]
[M02AA02, mofebutazone, The protein binding of Valproic acid can be decreased when combined with Mofebutazone.]
[M01AX22, morniflumate, The protein binding of Valproic acid can be decreased when combined with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Conivaptan can be decreased when combined with Valproic acid.]
[J05AF10, entecavir, The metabolism of Entecavir can be decreased when combined with Valproic acid.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Valproic acid.]
[M01AH05, etoricoxib, The protein binding of Valproic acid can be decreased when combined with Etoricoxib.]
[L01AX04, dacarbazine, The metabolism of Dacarbazine can be decreased when combined with Valproic acid.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Valproic acid is combined with Dantrolene.]
[J04BA02, dapsone, The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Valproic acid.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Valproic acid is combined with Deanol.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Valproic acid.]
[M01AX01, nabumetone, The protein binding of Valproic acid can be decreased when combined with Nabumetone.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Nordazepam.]
[C07AB12, nebivolol, The metabolism of Nebivolol can be decreased when combined with Valproic acid.]
[N06AX06, nefazodone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Niaprazine.]
[L02BB02, nilutamide, The metabolism of Nilutamide can be decreased when combined with Valproic acid.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Tiagabine.]
[G03DB04, nomegestrol, The metabolism of Nomegestrol can be increased when combined with Valproic acid.]
[C01CA23, theodrenaline, Valproic acid may increase the excretion rate of Theodrenaline which could result in a lower serum level and potentially a reduction in efficacy.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Valproic acid is combined with Cisatracurium.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Escitalopram.]
[G04BD08, solifenacin, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[A07EC03, olsalazine, The serum concentration of Valproic acid can be increased when it is combined with Olsalazine.]
[N06AA01, desipramine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Desipramine.]
[J01DH03, ertapenem, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Ertapenem.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Valproic acid.]
[M01AE12, oxaprozin, The protein binding of Valproic acid can be decreased when combined with Oxaprozin.]
[N03AF02, oxcarbazepine, The serum concentration of the active metabolites of Oxcarbazepine can be decreased when Oxcarbazepine is used in combination with Valproic acid.]
[S03BA01, dexamethasone, The excretion of Dexamethasone can be decreased when combined with Valproic acid.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Oxiracetam.]
[N04AA08, dexetimide, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Dexfenfluramine can be decreased when combined with Valproic acid.]
[A03AA01, oxyphencyclimine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Valproic acid can be increased when combined with Adalimumab.]
[N06BA02, dextroamphetamine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Valproic acid.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Valproic acid is combined with Dextromethorphan.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Valproic acid is combined with Paramethadione.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Clopidogrel can be decreased when combined with Valproic acid.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Valproic acid is combined with Diamorphine.]
[C04AD01, pentifylline, Valproic acid may increase the excretion rate of Pentifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Diazepam.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Phenacemide.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Phenol.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Phensuximide.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Valproic acid is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Cinchocaine.]
[S01BC03, diclofenac, The protein binding of Valproic acid can be decreased when combined with Diclofenac.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Valproic acid.]
[A03AA07, dicyclomine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[J05AF03, zalcitabine, The excretion of Zalcitabine can be decreased when combined with Valproic acid.]
[J05AF02, didanosine, The excretion of Didanosine can be decreased when combined with Valproic acid.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Valproic acid.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Pipamperone.]
[A03AB14, pipenzolate, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be decreased when combined with Valproic acid.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Valproic acid.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Valproic acid is combined with Diethylpropion.]
[L02AA01, diethylstilbestrol, The metabolism of Diethylstilbestrol can be increased when combined with Valproic acid.]
[C08CA03, isradipine, The risk or severity of QTc prolongation can be increased when Isradipine is combined with Valproic acid.]
[A03AB11, poldine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, The serum concentration of Valproic acid can be increased when it is combined with Diflunisal.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be decreased when combined with Valproic acid.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Valproic acid.]
[C02DB01, dihydralazine, The metabolism of Dihydralazine can be decreased when combined with Valproic acid.]
[C10AX09, ezetimibe, The metabolism of Ezetimibe can be decreased when combined with Valproic acid.]
[C04AE04, dihydroergocristine, The metabolism of Dihydroergocristine can be decreased when combined with Valproic acid.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be decreased when combined with Valproic acid.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Hydromorphone.]
[J05AE08, atazanavir, The metabolism of Valproic acid can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Valproic acid.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Pramocaine.]
[C08DB01, diltiazem, The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Valproic acid.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Valproic acid.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Valproic acid is combined with Pridinol.]
[R06AB03, dimethindene, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[M02AX03, dimethyl sulfoxide, The metabolism of Valproic acid can be decreased when combined with Dimethyl sulfoxide.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Progabide.]
[N06BC02, propentofylline, Valproic acid may increase the excretion rate of Propentofylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BB04, propyphenazone, The protein binding of Valproic acid can be decreased when combined with Propyphenazone.]
[M01AB14, proglumetacin, The protein binding of Valproic acid can be decreased when combined with Proglumetacin.]
[G02AD02, dinoprostone, The excretion of Valproic acid can be decreased when combined with Dinoprostone.]
[C05CA03, diosmin, The metabolism of Valproic acid can be decreased when combined with Diosmin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Proparacaine.]
[R03DA03, proxyphylline, Valproic acid may increase the excretion rate of Proxyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Valproic acid is combined with Diphenoxylate.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Quazepam.]
[C09AA06, quinapril, The excretion of Quinapril can be decreased when combined with Valproic acid.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Valproic acid is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Quinupramine.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Cisapride.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Valproic acid.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Valproic acid is combined with Remoxipride.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Valproic acid.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Valproic acid.]
[S02AA12, rifamycin SV, The metabolism of Valproic acid can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Valproic acid can be increased when combined with Rifapentine.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Valproic acid is combined with Riluzole.]
[N05AX08, risperidone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Risperidone.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Valproic acid.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Ropivacaine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Valproic acid.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be decreased when combined with Valproic acid.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be decreased when combined with Valproic acid.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be decreased when combined with Valproic acid.]
[S01BC05, ketorolac, The protein binding of Valproic acid can be decreased when combined with Ketorolac.]
[C01EB18, ranolazine, The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Valproic acid.]
[N02BA06, salsalate, The protein binding of Valproic acid can be decreased when combined with Salsalate.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Valproic acid.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Domperidone.]
[N06AA16, dothiepin, The metabolism of Dosulepin can be decreased when combined with Valproic acid.]
[N06AA12, doxepin, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be decreased when combined with Valproic acid.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Valproic acid.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Valproic acid is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Valproic acid.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Valproic acid.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Sibutramine.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be decreased when combined with Valproic acid.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Sodium phosphate, monobasic.]
[R03DA01, dyphylline, Valproic acid may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Sultopride is combined with Valproic acid.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Valproic acid is combined with Sumatriptan.]
[C07AB13, talinolol, The risk or severity of QTc prolongation can be increased when Talinolol is combined with Valproic acid.]
[J01CG02, tazobactam, The excretion of Valproic acid can be decreased when combined with Tazobactam.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Temafloxacin.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Temozolomide.]
[M01AC02, tenoxicam, The protein binding of Valproic acid can be decreased when combined with Tenoxicam.]
[D01BA02, terbinafine, The metabolism of Terbinafine can be decreased when combined with Valproic acid.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Terodiline.]
[A08AB01, orlistat, Orlistat can cause a decrease in the absorption of Valproic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Valproic acid is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Valproic acid is combined with Thiopropazate.]
[G04BD01, emepronium, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be decreased when combined with Valproic acid.]
[C09AA02, enalapril, The excretion of Valproic acid can be decreased when combined with Enalapril.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Tofisopam.]
[M01AG02, tolfenamic acid, The protein binding of Valproic acid can be decreased when combined with Tolfenamic acid.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Toloxatone.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Valproic acid.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Valproic acid.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Toremifene.]
[C03CA04, torsemide, The metabolism of Torasemide can be decreased when combined with Valproic acid.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Valproic acid is combined with Chloral hydrate.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Valproic acid is combined with Triclofos.]
[A03AB08, tridihexethyl, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Trimethobenzamide.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Valproic acid.]
[N04AA12, tropatepine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Valproic acid.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Valproic acid is combined with Urapidil.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Valproic acid.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Valproic acid is combined with Veralipride.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be decreased when combined with Valproic acid.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Epinastine is combined with Valproic acid.]
[N06AX16, venlafaxine, The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Venlafaxine.]
[S01EA01, epinephrine, The metabolism of Valproic acid can be decreased when combined with Epinephrine.]
[N05CF02, zolpidem, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, The protein binding of Valproic acid can be decreased when combined with Zomepirac.]
[N03AX15, zonisamide, The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Valproic acid.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Valproic acid.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Zotepine.]
[C02AC02, guanfacine, The serum concentration of Valproic acid can be increased when it is combined with Guanfacine.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Valproic acid.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Valproic acid is combined with Ergoloid mesylate.]
[N02CA02, ergotamine, The metabolism of Ergotamine can be decreased when combined with Valproic acid.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Valproic acid.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Estazolam.]
[A02BC02, pantoprazole, The excretion of Valproic acid can be decreased when combined with Pantoprazole.]
[H05BX01, cinacalcet, The metabolism of Cinacalcet can be decreased when combined with Valproic acid.]
[G03CA03, estradiol, The metabolism of Estradiol can be increased when combined with Valproic acid.]
[G03CA57, estrogens, conjugated (USP), The excretion of Valproic acid can be decreased when combined with Conjugated estrogens.]
[J04AK02, ethambutol, The metabolism of Valproic acid can be decreased when combined with Ethambutol.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Valproic acid.]
[C01CA15, gepefrine, The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Gepefrine.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Valproic acid.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be increased when combined with Valproic acid.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Valproic acid.]
[N04AA05, profenamine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The serum concentration of Valproic acid can be decreased when it is combined with Ethosuximide.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Valproic acid is combined with Ethotoin.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Ethyl chloride.]
[M01AC06, meloxicam, The protein binding of Valproic acid can be decreased when combined with Meloxicam.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Ethylmorphine.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Etidocaine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Valproic acid.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Valproic acid.]
[D05BB01, etretinate, Valproic acid may increase the Pseudotumor Cerebri activities of Etretinate.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Valproic acid is combined with Sertindole.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Valproic acid.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Valproic acid.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Valproic acid.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Valproic acid.]
[R06AX12, terfenadine, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Terfenadine.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Valproic acid is combined with Bupropion.]
[N06AB08, fluvoxamine, The metabolism of Valproic acid can be decreased when combined with Fluvoxamine.]
[C01BB03, tocainide, The metabolism of Tocainide can be decreased when combined with Valproic acid.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Encainide is combined with Valproic acid.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Valproic acid.]
[C10AA03, pravastatin, The excretion of Valproic acid can be decreased when combined with Pravastatin.]
[M01CB01, gold sodium thiomalate, The metabolism of Valproic acid can be decreased when combined with Sodium aurothiomalate.]
[A05AA01, chenodeoxycholic acid, The metabolism of Valproic acid can be decreased when combined with Chenodeoxycholic acid.]
[A02BA03, famotidine, The excretion of Valproic acid can be decreased when combined with Famotidine.]
[A16AA01, levocarnitine, The excretion of Levocarnitine can be decreased when combined with Valproic acid.]
[P02CA03, albendazole, The metabolism of Albendazole can be decreased when combined with Valproic acid.]
[C08CA02, felodipine, The risk or severity of QTc prolongation can be increased when Felodipine is combined with Valproic acid.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Fendiline is combined with Valproic acid.]
[N03AX26, fenfluramine, The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Fenfluramine.]
[M01AE04, fenoprofen, The protein binding of Valproic acid can be decreased when combined with Fenoprofen.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Valproic acid.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Valproic acid.]
[L01BB06, clofarabine, The excretion of Clofarabine can be decreased when combined with Valproic acid.]
[G04BD02, flavoxate, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Flecainide is combined with Valproic acid.]
[N02BG04, floctafenine, The protein binding of Valproic acid can be decreased when combined with Floctafenine.]
[J02AC01, fluconazole, The metabolism of Valproic acid can be decreased when combined with Fluconazole.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Flunarizine.]
[N05CD03, flunitrazepam, The metabolism of Valproic acid can be decreased when combined with Flunitrazepam.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Valproic acid is combined with Melitracen.]
[V03AZ01, ethanol, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC09, floxuridine, The metabolism of Valproic acid can be decreased when combined with Floxuridine.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Valproic acid.]
[N06AB03, fluoxetine, The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Fluphenazine.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Flurazepam.]
[S01BC04, flurbiprofen, The protein binding of Valproic acid can be decreased when combined with Flurbiprofen.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Valproic acid.]
[L02BB01, flutamide, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Flutamide.]
[V04CX02, folic acid, The serum concentration of Folic acid can be decreased when it is combined with Valproic acid.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Valproic acid.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Valproic acid is combined with Alcuronium.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Furazolidone.]
[C03CA01, furosemide, The excretion of Valproic acid can be decreased when combined with Furosemide.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Valproic acid is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Valproic acid.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Valproic acid.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Gallamine.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Gallopamil is combined with Valproic acid.]
[S01AD09, ganciclovir, The excretion of Valproic acid can be decreased when combined with Ganciclovir.]
[N03AA04, barbexaclone, The serum concentration of Barbexaclone can be increased when it is combined with Valproic acid.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Valproic acid is combined with Bifemelane.]
[C10AB04, gemfibrozil, The metabolism of Valproic acid can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Telavancin is combined with Valproic acid.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Valproic acid.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be decreased when combined with Valproic acid.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be decreased when combined with Valproic acid.]
[C01CA21, cafedrine, Valproic acid may increase the excretion rate of Cafedrine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AG04, etravirine, The metabolism of Etravirine can be decreased when combined with Valproic acid.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Valproic acid.]
[G03XA02, gestrinone, The metabolism of Gestrinone can be increased when combined with Valproic acid.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Valproic acid is combined with Alfentanil.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Valproic acid.]
[A10BB01, glyburide, The metabolism of Glyburide can be decreased when combined with Valproic acid.]
[A10BB09, gliclazide, The metabolism of Gliclazide can be decreased when combined with Valproic acid.]
[A10BB07, glipizide, The metabolism of Glipizide can be decreased when combined with Valproic acid.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Dexmedetomidine.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Glutethimide.]
[C05AE01, nitroglycerin, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Nitroglycerin.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be decreased when combined with Valproic acid.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Valproic acid.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Valproic acid.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Valproic acid.]
[B01AA12, fluindione, The metabolism of Fluindione can be decreased when combined with Valproic acid.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Goserelin is combined with Valproic acid.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Haloperidol.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Valproic acid is combined with Halothane.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Valproic acid.]
[N05AH04, quetiapine, The risk or severity of QTc prolongation can be increased when Quetiapine is combined with Valproic acid.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Valproic acid is combined with Iprazochrome.]
[L01CE02, irinotecan, The risk or severity of neutropenia can be increased when Valproic acid is combined with Irinotecan.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Valproic acid is combined with Allobarbital.]
[M04AA01, allopurinol, The excretion of Allopurinol can be decreased when combined with Valproic acid.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Valproic acid.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be decreased when combined with Valproic acid.]
[A07EC02, mesalamine, The serum concentration of Valproic acid can be increased when it is combined with Mesalazine.]
[N05CA16, hexobarbital, The serum concentration of Hexobarbital can be increased when it is combined with Valproic acid.]
[J05AG01, nevirapine, The metabolism of Valproic acid can be increased when combined with Nevirapine.]
[C08CA10, nilvadipine, The risk or severity of QTc prolongation can be increased when Nilvadipine is combined with Valproic acid.]
[M02AA26, nimesulide, The protein binding of Valproic acid can be decreased when combined with Nimesulide.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Valproic acid.]
[C03AA03, hydrochlorothiazide, The excretion of Hydrochlorothiazide can be decreased when combined with Valproic acid.]
[R05DA03, hydrocodone, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[S02BA01, hydrocortisone, The excretion of Hydrocortisone can be decreased when combined with Valproic acid.]
[G04BD06, propiverine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[P01BA02, hydroxychloroquine, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Hydroxychloroquine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Valproic acid is combined with Prothipendyl.]
[L01XX05, hydroxyurea, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Hydroxyurea.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Hydroxyzine.]
[J04AB04, rifabutin, The metabolism of Valproic acid can be increased when combined with Rifabutin.]
[R02AX02, ibuprofen, The protein binding of Valproic acid can be decreased when combined with Ibuprofen.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Valproic acid.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Valproic acid.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Valproic acid is combined with Sufentanil.]
[N06AA02, imipramine, The risk or severity of QTc prolongation can be increased when Imipramine is combined with Valproic acid.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Valproic acid.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Valproic acid.]
[M03BX02, tizanidine, The metabolism of Tizanidine can be decreased when combined with Valproic acid.]
[L01CE01, topotecan, Valproic acid may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Valproic acid.]
[S01BC01, indomethacin, The protein binding of Valproic acid can be decreased when combined with Indomethacin.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Valproic acid is combined with Milnacipran.]
[A03AA30, piperidolate, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Articaine.]
[A10BH01, sitagliptin, The excretion of Sitagliptin can be decreased when combined with Valproic acid.]
[V08AB02, iohexol, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Iohexol.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Valproic acid.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Valproic acid is combined with Ramelteon.]
[R06AE01, buclizine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[C10AA06, cerivastatin, The metabolism of Cerivastatin can be decreased when combined with Valproic acid.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Valproic acid.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Valproic acid is combined with Alprenolol.]
[J05AF04, stavudine, The excretion of Stavudine can be decreased when combined with Valproic acid.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Valproic acid is combined with Iprindole.]
[G04BE01, alprostadil, The excretion of Alprostadil can be decreased when combined with Valproic acid.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Iproniazid.]
[J05AB13, penciclovir, The metabolism of Penciclovir can be decreased when combined with Valproic acid.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Isocarboxazid.]
[P01AX06, atovaquone, The metabolism of Valproic acid can be decreased when combined with Atovaquone.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Valproic acid.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Entacapone.]
[J04AC01, isoniazid, The metabolism of Valproic acid can be decreased when combined with Isoniazid.]
[C01DA14, isosorbide mononitrate, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Isosorbide mononitrate.]
[C05AE02, isosorbide dinitrate, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Isosorbide dinitrate.]
[D10BA01, isotretinoin, Valproic acid may increase the Pseudotumor Cerebri activities of Isotretinoin.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Valproic acid.]
[L04AC07, tocilizumab, The metabolism of Valproic acid can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Valproic acid is combined with Ketanserin.]
[B01AC22, prasugrel, The metabolism of Prasugrel can be decreased when combined with Valproic acid.]
[J02AB02, ketoconazole, The metabolism of Valproic acid can be decreased when combined with Ketoconazole.]
[H02CA04, levoketoconazole, The metabolism of Valproic acid can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, The serum concentration of Olanzapine can be decreased when it is combined with Valproic acid.]
[M02AA10, ketoprofen, The protein binding of Valproic acid can be decreased when combined with Ketoprofen.]
[V03AC03, deferasirox, The metabolism of Valproic acid can be decreased when combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Valproic acid can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Valproic acid.]
[N04BC09, rotigotine, Valproic acid may increase the sedative activities of Rotigotine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Valproic acid.]
[M01AE11, tiaprofenic acid, The protein binding of Valproic acid can be decreased when combined with Tiaprofenic acid.]
[D11AX02, gamma-linolenic acid, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Gamolenic acid.]
[C07AG01, labetalol, The metabolism of Labetalol can be decreased when combined with Valproic acid.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Valproic acid.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Lacosamide.]
[G03AD01, levonorgestrel, The metabolism of Levonorgestrel can be increased when combined with Valproic acid.]
[N04BA01, levodopa, The risk or severity of adverse effects can be increased when Valproic acid is combined with Levodopa.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Valproic acid.]
[N06BA13, armodafinil, The metabolism of Valproic acid can be decreased when combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Valproic acid.]
[N02CA07, lisuride, The risk or severity of adverse effects can be increased when Valproic acid is combined with Lisuride.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Lofepramine.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Loperamide is combined with Valproic acid.]
[N05BA06, lorazepam, The serum concentration of Lorazepam can be increased when it is combined with Valproic acid.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Valproic acid.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Loxapine.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be increased when combined with Valproic acid.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be decreased when combined with Valproic acid.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Valproic acid can be increased when used in combination with Magnesium sulfate.]
[L01EA03, nilotinib, The metabolism of Nilotinib can be decreased when combined with Valproic acid.]
[N06AA21, maprotiline, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Valproic acid is combined with Mazindol.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Meclizine.]
[M02AA18, meclofenamic acid, The protein binding of Valproic acid can be decreased when combined with Meclofenamic acid.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Medazepam.]
[P01BC02, mefloquine, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Mefloquine.]
[N05CH01, melatonin, The excretion of Valproic acid can be decreased when combined with Melatonin.]
[N06DX01, memantine, The metabolism of Valproic acid can be decreased when combined with Memantine.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Meperidine.]
[C01CA11, mephentermine, The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Mephentermine.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Valproic acid is combined with Mephenytoin.]
[N03AA01, mephobarbital, The serum concentration of Phenobarbital, an active metabolite of Methylphenobarbital, can be increased when used in combination with Valproic acid.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Valproic acid is combined with Meprobamate.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Valproic acid is combined with Meptazinol.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Valproic acid.]
[N05AX13, paliperidone, The serum concentration of Paliperidone can be increased when it is combined with Valproic acid.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Valproic acid.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Valproic acid.]
[N06BA03, methamphetamine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Metamfetamine.]
[A03AB07, methantheline, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Valproic acid is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Methaqualone.]
[J05AF05, lamivudine, The excretion of Lamivudine can be decreased when combined with Valproic acid.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Valproic acid is combined with Metharbital.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Valproic acid is combined with Metergoline.]
[H03BB02, methimazole, The metabolism of Valproic acid can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Valproic acid may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Valproic acid is combined with Methocarbamol.]
[N05CA15, methohexital, The serum concentration of Methohexital can be increased when it is combined with Valproic acid.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Valproic acid is combined with Ziconotide.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be decreased when combined with Valproic acid.]
[N05AA02, methotrimeprazine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[D05BA02, methoxsalen, The metabolism of Valproic acid can be decreased when combined with Methoxsalen.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Valproic acid is combined with Methoxyflurane.]
[V04CG05, methylene blue, Valproic acid may increase the serotonergic activities of Methylene blue.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Valproic acid.]
[N06BA04, methylphenidate, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Methylphenidate.]
[N03AF03, rufinamide, The serum concentration of Rufinamide can be increased when it is combined with Valproic acid.]
[G03EK01, methyltestosterone, The excretion of Valproic acid can be increased when combined with Methyltestosterone.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Valproic acid is combined with Methyprylon.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Valproic acid.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Valproic acid.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Valproic acid.]
[V04CD01, metyrapone, The metabolism of Valproic acid can be decreased when combined with Metyrapone.]
[C01BB02, mexiletine, The metabolism of Mexiletine can be decreased when combined with Valproic acid.]
[N06AX03, mianserin, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Mianserin.]
[S02AA13, miconazole, The metabolism of Valproic acid can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The protein binding of Valproic acid can be decreased when combined with Aminophenazone.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Valproic acid.]
[G03XB01, mifepristone, The metabolism of Mifepristone can be increased when combined with Valproic acid.]
[C09CA03, valsartan, The metabolism of Valsartan can be decreased when combined with Valproic acid.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Valproic acid.]
[D11AX01, minoxidil, The metabolism of Minoxidil can be decreased when combined with Valproic acid.]
[N06BA12, lisdexamfetamine, The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Lisdexamfetamine.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Molindone.]
[C01BD01, amiodarone, The metabolism of Amiodarone can be decreased when combined with Valproic acid.]
[N06AA09, amitriptyline, The metabolism of Valproic acid can be decreased when combined with Amitriptyline.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Valproic acid.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Valproic acid is combined with Palonosetron.]
[L04AB05, certolizumab pegol, The metabolism of Valproic acid can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Valproic acid can be decreased when combined with Eltrombopag.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Valproic acid.]
[L04AA06, mycophenolic acid, The metabolism of Mycophenolic acid can be decreased when combined with Valproic acid.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Valproic acid is combined with Vecuronium.]
[N05CA02, amobarbital, The serum concentration of Amobarbital can be increased when it is combined with Valproic acid.]
[J05AJ01, raltegravir, The metabolism of Raltegravir can be decreased when combined with Valproic acid.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Valproic acid.]
[R03BB01, ipratropium bromide, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[G03XC01, raloxifene, The metabolism of Valproic acid can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.]
[N03AB05, fosphenytoin, The serum concentration of Fosphenytoin can be decreased when it is combined with Valproic acid.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Valproic acid is combined with Ropinirole.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Valproic acid is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Nalbuphine.]
[V03AB15, naloxone, The metabolism of Naloxone can be decreased when combined with Valproic acid.]
[N07BB04, naltrexone, The metabolism of Naltrexone can be decreased when combined with Valproic acid.]
[L04AC03, anakinra, The metabolism of Valproic acid can be increased when combined with Anakinra.]
[N06BA01, amphetamine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Valproic acid.]
[M02AA12, naproxen, The protein binding of Valproic acid can be decreased when combined with Naproxen.]
[A10BG01, troglitazone, The metabolism of Valproic acid can be decreased when combined with Troglitazone.]
[N06AX21, duloxetine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Tolcapone.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Valproic acid.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Valproic acid.]
[L02BG04, letrozole, The metabolism of Valproic acid can be decreased when combined with Letrozole.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Valproic acid is combined with Remifentanil.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Valproic acid.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Valproic acid.]
[J02AA01, amphotericin B, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Amphotericin B.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Desvenlafaxine.]
[C09CA07, telmisartan, The metabolism of Valproic acid can be decreased when combined with Telmisartan.]
[J05AB11, valacyclovir, The excretion of Valaciclovir can be decreased when combined with Valproic acid.]
[M04AA03, febuxostat, The metabolism of Febuxostat can be decreased when combined with Valproic acid.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Nialamide.]
[C08CA04, nicardipine, The metabolism of Valproic acid can be decreased when combined with Nicardipine.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be decreased when combined with Valproic acid.]
[N07BA01, nicotine, The metabolism of Valproic acid can be decreased when combined with Nicotine.]
[C08CA05, nifedipine, Valproic acid may increase the hypotensive activities of Nifedipine.]
[M02AA17, niflumic acid, The protein binding of Valproic acid can be decreased when combined with Niflumic acid.]
[V03AB22, amyl nitrite, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Amyl Nitrite.]
[C08CA06, nimodipine, Nimodipine can cause an increase in the absorption of Valproic acid resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Nitrazepam.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Valproic acid.]
[R07AX01, nitric oxide, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Nitric Oxide.]
[J01XE01, nitrofurantoin, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Nitrofurantoin.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Valproic acid is combined with Zaleplon.]
[N04BC05, pramipexole, Valproic acid may increase the sedative activities of Pramipexole.]
[C02DD01, nitroprusside, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Nitroprusside.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Nomifensine.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be increased when combined with Valproic acid.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Valproic acid.]
[G03AC07, norgestrienone, The metabolism of Norgestrienone can be increased when combined with Valproic acid.]
[C02KX01, bosentan, The metabolism of Bosentan can be decreased when combined with Valproic acid.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Valproic acid.]
[R05DA07, noscapine, The metabolism of Valproic acid can be decreased when combined with Noscapine.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Valproic acid.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Valproic acid.]
[L04AC04, rilonacept, The metabolism of Valproic acid can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be decreased when combined with Valproic acid.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Valproic acid is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Valproic acid is combined with Opium.]
[C01AC01, ouabain, The excretion of Valproic acid can be decreased when combined with Ouabain.]
[A14AA08, oxandrolone, The metabolism of Valproic acid can be decreased when combined with Oxandrolone.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Oxazepam.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Valproic acid.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Valproic acid is combined with Oxprenolol.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Oxycodone.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Oxymorphone.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Oxypertine.]
[S01BC02, oxyphenbutazone, The protein binding of Valproic acid can be decreased when combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[S01AA04, oxytetracycline, The excretion of Valproic acid can be decreased when combined with Oxytetracycline.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Valproic acid.]
[V04CH30, 4-aminohippuric acid, The excretion of Valproic acid can be decreased when combined with Aminohippuric acid.]
[J04AA01, aminosalicylic acid, The serum concentration of Valproic acid can be increased when it is combined with Aminosalicylic acid.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Asenapine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Valproic acid.]
[M03AC01, pancuronium, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[G03DB06, chlormadinone, The metabolism of Chlormadinone can be increased when combined with Valproic acid.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Valproic acid.]
[N05CC05, paraldehyde, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Valproic acid is combined with Pargyline.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Valproic acid.]
[G04BD11, fesoterodine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Valproic acid is combined with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Penfluridol is combined with Valproic acid.]
[S01AA14, penicillin G, The excretion of Valproic acid can be decreased when combined with Benzylpenicillin.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Pentazocine.]
[N05CA01, pentobarbital, The serum concentration of Pentobarbital can be increased when it is combined with Valproic acid.]
[C04AD03, pentoxifylline, Valproic acid may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Perazine.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Pergolide.]
[C08EX02, perhexiline, The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Valproic acid.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Perphenazine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Valproic acid.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Phenazocine.]
[G04BX06, phenazopyridine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Phenazopyridine.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Phenelzine.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Valproic acid.]
[N03AA02, phenobarbital, The serum concentration of Phenobarbital, an active metabolite of Phenobarbital, can be increased when used in combination with Valproic acid.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Phenoperidine.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Valproic acid.]
[A08AA01, phentermine, The risk or severity of serotonin syndrome can be increased when Phentermine is combined with Valproic acid.]
[M02AA01, phenylbutazone, The protein binding of Valproic acid can be decreased when combined with Phenylbutazone.]
[A02BC06, dexlansoprazole, The metabolism of Dexlansoprazole can be decreased when combined with Valproic acid.]
[R01BA01, phenylpropanolamine, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Phenylpropanolamine.]
[N03AB02, phenytoin, The serum concentration of Phenytoin can be decreased when it is combined with Valproic acid.]
[L01XF02, alitretinoin, Valproic acid may increase the Pseudotumor Cerebri activities of Alitretinoin.]
[L04AB06, golimumab, The metabolism of Valproic acid can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Valproic acid.]
[N07BB03, acamprosate, The excretion of Acamprosate can be decreased when combined with Valproic acid.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be decreased when combined with Valproic acid.]
[J05AB12, cidofovir, The excretion of Cidofovir can be decreased when combined with Valproic acid.]
[C08CX01, mibefradil, The risk or severity of QTc prolongation can be increased when Mibefradil is combined with Valproic acid.]
[S01EB01, pilocarpine, The metabolism of Valproic acid can be decreased when combined with Pilocarpine.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Valproic acid.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Valproic acid is combined with Pindolol.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Valproic acid.]
[J01CA12, piperacillin, The excretion of Piperacillin can be decreased when combined with Valproic acid.]
[J05AE01, saquinavir, The risk or severity of QTc prolongation can be increased when Saquinavir is combined with Valproic acid.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Pipotiazine.]
[A02BX03, pirenzepine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Piritramide.]
[S01BC06, piroxicam, The protein binding of Valproic acid can be decreased when combined with Piroxicam.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Grepafloxacin.]
[N02CX01, pizotyline, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[J05AG02, delavirdine, The metabolism of Valproic acid can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Irbesartan can be decreased when combined with Valproic acid.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Valproic acid is combined with Proxibarbal.]
[D05AX05, tazarotene, Valproic acid may increase the Pseudotumor Cerebri activities of Tazarotene.]
[A10BG02, rosiglitazone, The metabolism of Rosiglitazone can be decreased when combined with Valproic acid.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Valproic acid is combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Valproic acid can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The excretion of Polythiazide can be decreased when combined with Valproic acid.]
[J05AE03, ritonavir, The metabolism of Valproic acid can be increased when combined with Ritonavir.]
[A10BH03, saxagliptin, The excretion of Saxagliptin can be decreased when combined with Valproic acid.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Valproic acid.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Valproic acid.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Prazepam.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Valproic acid.]
[H02AB07, prednisone, The metabolism of Valproic acid can be increased when combined with Prednisone.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Antazoline is combined with Valproic acid.]
[M02AA16, feprazone, The protein binding of Valproic acid can be decreased when combined with Feprazone.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Prenylamine is combined with Valproic acid.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Prilocaine.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Primaquine is combined with Valproic acid.]
[N03AA03, primidone, The serum concentration of Phenobarbital, an active metabolite of Primidone, can be increased when used in combination with Valproic acid.]
[M04AB01, probenecid, The metabolism of Valproic acid can be decreased when combined with Probenecid.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Probucol is combined with Valproic acid.]
[C01BA02, procainamide, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Procainamide.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Procarbazine.]
[C10AB05, fenofibrate, The metabolism of Fenofibrate can be decreased when combined with Valproic acid.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Valproic acid.]
[N04AA04, procyclidine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, The metabolism of Progesterone can be increased when combined with Valproic acid.]
[N05AA03, promazine, The risk or severity of QTc prolongation can be increased when Promazine is combined with Valproic acid.]
[R06AD02, promethazine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[C01BC03, propafenone, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Valproic acid.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Propanidid.]
[A03AB05, propantheline, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[R06AX26, fexofenadine, The excretion of Fexofenadine can be decreased when combined with Valproic acid.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Periciazine.]
[N05CM06, propiomazine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be decreased when combined with Valproic acid.]
[N01AX10, propofol, The serum concentration of Propofol can be increased when it is combined with Valproic acid.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Valproic acid is combined with Dextropropoxyphene.]
[C07AA05, propranolol, The serum concentration of Propranolol can be increased when it is combined with Valproic acid.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Valproic acid is combined with Rizatriptan.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Valproic acid.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Valproic acid.]
[R01BA02, pseudoephedrine, The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Pseudoephedrine.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Valproic acid.]
[A03AB15, diphemanil, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Valproic acid.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Valproic acid is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Valproic acid is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Valproic acid is combined with Pyrantel.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Valproic acid.]
[C01BA01, quinidine, The metabolism of Quinidine can be decreased when combined with Valproic acid.]
[P01BC01, quinine, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Quinine.]
[A02BA02, ranitidine, The excretion of Ranitidine can be decreased when combined with Valproic acid.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Valproic acid.]
[J04AB02, rifampin, The metabolism of Valproic acid can be increased when combined with Rifampicin.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Valproic acid is combined with Oxitriptan.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Valproic acid.]
[N02BA05, salicylamide, The protein binding of Valproic acid can be decreased when combined with Salicylamide.]
[A07EC01, sulfasalazine, The serum concentration of Valproic acid can be increased when it is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The serum concentration of Valproic acid can be increased when it is combined with Salicylic acid.]
[S01FA02, scopolamine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, The serum concentration of Secobarbital can be increased when it is combined with Valproic acid.]
[N04BD01, selegiline, The risk or severity of adverse effects can be increased when Valproic acid is combined with Selegiline.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Sotalol.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Valproic acid.]
[S02DA03, antipyrine, The protein binding of Valproic acid can be decreased when combined with Antipyrine.]
[G03XB02, ulipristal, The metabolism of Ulipristal can be increased when combined with Valproic acid.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Valproic acid.]
[J01EC02, sulfadiazine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Sulfadiazine.]
[S01AB01, sulfamethizole, The metabolism of Valproic acid can be decreased when combined with Sulfamethizole.]
[J01EC01, sulfamethoxazole, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Valproic acid.]
[J01EC03, sulfamoxole, The metabolism of Valproic acid can be decreased when combined with Sulfamoxole.]
[J01EB04, sulfapyridine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Sulfapyridine.]
[M04AB02, sulfinpyrazone, The metabolism of Valproic acid can be decreased when combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Valproic acid.]
[M01AB02, sulindac, The protein binding of Valproic acid can be decreased when combined with Sulindac.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Valproic acid.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Valproic acid is combined with Sulthiame.]
[M01AE07, suprofen, The protein binding of Valproic acid can be decreased when combined with Suprofen.]
[A10BB04, glibornuride, The metabolism of Glibornuride can be decreased when combined with Valproic acid.]
[M01AX04, apazone, The protein binding of Valproic acid can be decreased when combined with Azapropazone.]
[L01BB02, mercaptopurine, The excretion of Mercaptopurine can be decreased when combined with Valproic acid.]
[N06DA01, tacrine, The metabolism of Tacrine can be decreased when combined with Valproic acid.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Valproic acid.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Valproic acid.]
[L01CB02, teniposide, The metabolism of Teniposide can be decreased when combined with Valproic acid.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Valproic acid.]
[G03BA03, testosterone, The excretion of Valproic acid can be increased when combined with Testosterone.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Tetracaine.]
[S03AA02, tetracycline, The excretion of Valproic acid can be decreased when combined with Tetracycline.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Valproic acid.]
[A04AD10, dronabinol, The serum concentration of Dronabinol can be increased when it is combined with Valproic acid.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Valproic acid.]
[L04AX02, thalidomide, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, Valproic acid may increase the excretion rate of Theobromine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Valproic acid.]
[P02CA02, thiabendazole, The metabolism of Thiabendazole can be decreased when combined with Valproic acid.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Eribulin is combined with Valproic acid.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Thiethylperazine.]
[L01AC01, thiotepa, The metabolism of Thiotepa can be decreased when combined with Valproic acid.]
[N05CA19, thiopental, The serum concentration of Thiopental can be increased when it is combined with Valproic acid.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Thioproperazine.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Valproic acid.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Valproic acid is combined with Tiapride.]
[B01AC05, ticlopidine, The metabolism of Valproic acid can be decreased when combined with Ticlopidine.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Tilidine.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Timolol is combined with Valproic acid.]
[A10BB05, tolazamide, The metabolism of Tolazamide can be decreased when combined with Valproic acid.]
[V04CA01, tolbutamide, The metabolism of Tolbutamide can be decreased when combined with Valproic acid.]
[M02AA21, tolmetin, The protein binding of Valproic acid can be decreased when combined with Tolmetin.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Tramadol.]
[N06AF04, tranylcypromine, The metabolism of Valproic acid can be decreased when combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Valproic acid.]
[L01XF01, tretinoin, Valproic acid may increase the Pseudotumor Cerebri activities of Tretinoin.]
[C03DB02, triamterene, The metabolism of Triamterene can be decreased when combined with Valproic acid.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Triazolam.]
[A03AB12, mepenzolate, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Trifluoperazine.]
[S01AD02, trifluridine, The excretion of Trifluridine can be decreased when combined with Valproic acid.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Valproic acid is combined with Trifluperidol.]
[N05AA05, triflupromazine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[N04AA01, trihexyphenidyl, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[A03AA05, trimebutine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Valproic acid.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Valproic acid.]
[J01EA01, trimethoprim, The metabolism of Trimethoprim can be decreased when combined with Valproic acid.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Valproic acid.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Valproic acid.]
[A03BB01, butylscopolamine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[N06AX24, vilazodone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Valproic acid.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Tubocurarine.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Valproic acid.]
[L01EX04, vandetanib, The metabolism of Vandetanib can be decreased when combined with Valproic acid.]
[A10BH05, linagliptin, The metabolism of Linagliptin can be decreased when combined with Valproic acid.]
[J05AG05, rilpivirine, The metabolism of Valproic acid can be decreased when combined with Rilpivirine.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Valproic acid.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Valproic acid.]
[B01AC24, ticagrelor, The metabolism of Valproic acid can be decreased when combined with Ticagrelor.]
[C08DA01, verapamil, The metabolism of Verapamil can be decreased when combined with Valproic acid.]
[N06AX09, viloxazine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Vinblastine can be decreased when combined with Valproic acid.]
[L01CA02, vincristine, The metabolism of Vincristine can be decreased when combined with Valproic acid.]
[L01CA03, vindesine, The metabolism of Vindesine can be decreased when combined with Valproic acid.]
[S01XA02, vitamin A, Valproic acid may increase the Pseudotumor Cerebri activities of Vitamin A.]
[B01AA03, warfarin, The serum concentration of Warfarin can be increased when it is combined with Valproic acid.]
[J05AF01, zidovudine, The serum concentration of Zidovudine can be increased when it is combined with Valproic acid.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Valproic acid can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Levetiracetam.]
[L01EC01, vemurafenib, The metabolism of Vemurafenib can be decreased when combined with Valproic acid.]
[L01FX05, brentuximab vedotin, The metabolism of Brentuximab vedotin can be decreased when combined with Valproic acid.]
[L01ED01, crizotinib, The metabolism of Crizotinib can be decreased when combined with Valproic acid.]
[R03DC01, zafirlukast, The metabolism of Valproic acid can be decreased when combined with Zafirlukast.]
[A02BC04, rabeprazole, The metabolism of Rabeprazole can be decreased when combined with Valproic acid.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Valproic acid.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Drospirenone can be increased when combined with Valproic acid.]
[N02BA01, aspirin, The metabolism of Valproic acid can be decreased when combined with Acetylsalicylic acid.]
[L01EJ01, ruxolitinib, The metabolism of Ruxolitinib can be decreased when combined with Valproic acid.]
[G04BD07, tolterodine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[J01DH04, doripenem, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Doripenem.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Valproic acid.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Valproic acid is combined with Atracurium.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Atropine is combined with Valproic acid.]
[L01XJ01, vismodegib, The metabolism of Vismodegib can be decreased when combined with Valproic acid.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Valproic acid.]
[B03XA04, peginesatide, The risk or severity of Thrombosis can be increased when Peginesatide is combined with Valproic acid.]
[L04AX01, azathioprine, The metabolism of Azathioprine can be decreased when combined with Valproic acid.]
[J01CA09, azlocillin, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Azlocillin.]
[G04BE10, avanafil, The metabolism of Avanafil can be decreased when combined with Valproic acid.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Valproic acid.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Valproic acid is combined with Lorcaserin.]
[G04BD12, mirabegron, The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Valproic acid.]
[J05AJ02, elvitegravir, The metabolism of Elvitegravir can be decreased when combined with Valproic acid.]
[L02BB04, enzalutamide, The serum concentration of Valproic acid can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Bosutinib can be decreased when combined with Valproic acid.]
[L04AA31, teriflunomide, The excretion of Valproic acid can be decreased when combined with Teriflunomide.]
[L01EX05, regorafenib, The metabolism of Regorafenib can be decreased when combined with Valproic acid.]
[N05CA04, barbital, The serum concentration of Barbital can be increased when it is combined with Valproic acid.]
[J05AE04, nelfinavir, The metabolism of Valproic acid can be increased when combined with Nelfinavir.]
[L01AA09, bendamustine, The metabolism of Bendamustine can be decreased when combined with Valproic acid.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Valproic acid.]
[N04BD02, rasagiline, The risk or severity of adverse effects can be increased when Valproic acid is combined with Rasagiline.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Valproic acid is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Valproic acid is combined with Donepezil.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Valproic acid.]
[L04AA29, tofacitinib, The metabolism of Tofacitinib can be decreased when combined with Valproic acid.]
[N02CC03, zolmitriptan, The metabolism of Zolmitriptan can be decreased when combined with Valproic acid.]
[R06AC06, thonzylamine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Valproic acid is combined with Diethyl ether.]
[L01EX07, cabozantinib, The metabolism of Cabozantinib can be decreased when combined with Valproic acid.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Valproic acid.]
[G04BE03, sildenafil, The metabolism of Sildenafil can be decreased when combined with Valproic acid.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Valproic acid.]
[B01AF02, apixaban, The metabolism of Apixaban can be decreased when combined with Valproic acid.]
[C10AX12, lomitapide, The metabolism of Lomitapide can be decreased when combined with Valproic acid.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Bedaquiline is combined with Valproic acid.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Bencyclane is combined with Valproic acid.]
[A16AX09, glycerol phenylbutyrate, The therapeutic efficacy of Glycerol phenylbutyrate can be decreased when used in combination with Valproic acid.]
[L04AX06, pomalidomide, The metabolism of Pomalidomide can be decreased when combined with Valproic acid.]
[G03XC05, ospemifene, The metabolism of Ospemifene can be decreased when combined with Valproic acid.]
[N02BA10, benorilate, The protein binding of Valproic acid can be decreased when combined with Benorilate.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Valproic acid is combined with Benperidol.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Gemifloxacin is combined with Valproic acid.]
[M04AB03, benzbromarone, The metabolism of Valproic acid can be decreased when combined with Benzbromarone.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Valproic acid.]
[A06AX06, tegaserod, The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Tegaserod.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Benzocaine.]
[M01AH01, celecoxib, The protein binding of Valproic acid can be decreased when combined with Celecoxib.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Valproic acid is combined with Naratriptan.]
[L04AA18, everolimus, The metabolism of Everolimus can be decreased when combined with Valproic acid.]
[N04AC01, benztropine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Valproic acid can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The protein binding of Valproic acid can be decreased when combined with Benzydamine.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Valproic acid is combined with Levomilnacipran.]
[J05AJ03, dolutegravir, The excretion of Valproic acid can be decreased when combined with Dolutegravir.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Bepridil.]
[A05AA03, cholic acid, The excretion of Valproic acid can be decreased when combined with Cholic Acid.]
[G03XC02, bazedoxifene, The metabolism of Bazedoxifene can be decreased when combined with Valproic acid.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Valproic acid.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Vortioxetine.]
[G03AC08, etonogestrel, The metabolism of Etonogestrel can be increased when combined with Valproic acid.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Eslicarbazepine.]
[D01AC18, luliconazole, The serum concentration of Valproic acid can be increased when it is combined with Luliconazole.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Valproic acid is combined with Vigabatrin.]
[A10BK01, dapagliflozin, The metabolism of Dapagliflozin can be decreased when combined with Valproic acid.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Valproic acid is combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Valproic acid can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Valproic acid can be increased when combined with Apremilast.]
[S03BA03, betamethasone, The metabolism of Valproic acid can be increased when combined with Betamethasone.]
[S01ED02, betaxolol, The metabolism of Betaxolol can be decreased when combined with Valproic acid.]
[V03AB34, fomepizole, The metabolism of Valproic acid can be decreased when combined with Fomepizole.]
[L04AC11, siltuximab, The metabolism of Valproic acid can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Ceritinib can be decreased when combined with Valproic acid.]
[B01AC26, vorapaxar, The metabolism of Vorapaxar can be decreased when combined with Valproic acid.]
[A03BA03, hyoscyamine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The serum concentration of Acenocoumarol can be increased when it is combined with Valproic acid.]
[L01XH04, belinostat, The metabolism of Belinostat can be decreased when combined with Valproic acid.]
[L01EM01, idelalisib, The metabolism of Idelalisib can be decreased when combined with Valproic acid.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Alfaxalone.]
[N07XX08, tafamidis, The excretion of Valproic acid can be decreased when combined with Tafamidis.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Valproic acid.]
[D11AA01, glycopyrronium, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The metabolism of Eliglustat can be decreased when combined with Valproic acid.]
[J01XA05, oritavancin, The metabolism of Valproic acid can be decreased when combined with Oritavancin.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Acepromazine.]
[N04AA02, biperiden, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Valproic acid.]
[L01EX09, nintedanib, The metabolism of Nintedanib can be decreased when combined with Valproic acid.]
[J05AP09, dasabuvir, The metabolism of Valproic acid can be decreased when combined with Dasabuvir.]
[L01XK01, olaparib, The metabolism of Olaparib can be decreased when combined with Valproic acid.]
[B01AA01, dicumarol, The metabolism of Dicoumarol can be decreased when combined with Valproic acid.]
[N06AX11, mirtazapine, Valproic acid may increase the serotonergic activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Valproic acid can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The metabolism of Palbociclib can be decreased when combined with Valproic acid.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Lenvatinib is combined with Valproic acid.]
[L01XH03, panobinostat, The metabolism of Panobinostat can be decreased when combined with Valproic acid.]
[N02BE01, acetaminophen, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Acetaminophen.]
[L01DC01, bleomycin, The serum concentration of Valproic acid can be decreased when it is combined with Bleomycin.]
[A03AA09, difemerine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Ivabradine.]
[J05AF08, adefovir dipivoxil, The excretion of Adefovir dipivoxil can be decreased when combined with Valproic acid.]
[J05AP06, asunaprevir, The metabolism of Asunaprevir can be decreased when combined with Valproic acid.]
[A07DA06, eluxadoline, The excretion of Eluxadoline can be decreased when combined with Valproic acid.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Valproic acid is combined with Brexpiprazole.]
[L01XJ02, sonidegib, The metabolism of Sonidegib can be decreased when combined with Valproic acid.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Valproic acid is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Cariprazine.]
[M02AA25, aceclofenac, The protein binding of Valproic acid can be decreased when combined with Aceclofenac.]
[M01AB11, acemetacin, The protein binding of Valproic acid can be decreased when combined with Acemetacin.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Acetazolamide.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Acetophenazine.]
[D05BB02, acitretin, Valproic acid may increase the Pseudotumor Cerebri activities of Acitretin.]
[A02BC03, lansoprazole, The metabolism of Valproic acid can be decreased when combined with Lansoprazole.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Valproic acid.]
[J02AC05, isavuconazole, The metabolism of Valproic acid can be decreased when combined with Isavuconazole.]
[L01EB04, osimertinib, The metabolism of Osimertinib can be decreased when combined with Valproic acid.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be decreased when it is combined with Valproic acid.]
[L01EE02, cobimetinib, The metabolism of Cobimetinib can be decreased when combined with Valproic acid.]
[L01XG03, ixazomib, The metabolism of Ixazomib can be decreased when combined with Valproic acid.]
[L01ED03, alectinib, The metabolism of Alectinib can be decreased when combined with Valproic acid.]
[A10BB31, acetohexamide, The metabolism of Acetohexamide can be decreased when combined with Valproic acid.]
[G04CA01, alfuzosin, The metabolism of Alfuzosin can be decreased when combined with Valproic acid.]
[M04AB05, lesinurad, The metabolism of Lesinurad can be decreased when combined with Valproic acid.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Valproic acid is combined with Aprobarbital.]
[M01AE16, alminoprofen, The protein binding of Valproic acid can be decreased when combined with Alminoprofen.]
[N02BA02, aloxiprin, The serum concentration of Valproic acid can be increased when it is combined with Aloxiprin.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Brivaracetam.]
[L01XX52, venetoclax, The metabolism of Venetoclax can be decreased when combined with Valproic acid.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Bromazepam.]
[N04BC01, bromocriptine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Bromocriptine.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Alverine.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Valproic acid.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Valproic acid is combined with Amineptine.]
[N05AX17, pimavanserin, The metabolism of Pimavanserin can be decreased when combined with Valproic acid.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Aniracetam.]
[M02AA09, bufexamac, The protein binding of Valproic acid can be decreased when combined with Bufexamac.]
[C03CA02, bumetanide, The excretion of Valproic acid can be decreased when combined with Bumetanide.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Bupivacaine.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Bupranolol is combined with Valproic acid.]
[N07BC01, buprenorphine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Valproic acid.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Buspirone.]
[L01AB01, busulfan, The metabolism of Busulfan can be decreased when combined with Valproic acid.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Artemether.]
[M02AA03, clofezone, The metabolism of Rabeprazole can be decreased when combined with Valproic acid.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Valproic acid is combined with Butorphanol.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Valproic acid.]
[S01GX07, azelastine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Valproic acid can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Valproic acid.]
[L01EF02, ribociclib, The metabolism of Ribociclib can be decreased when combined with Valproic acid.]
[A07EC04, balsalazide, The serum concentration of Valproic acid can be increased when it is combined with Balsalazide.]
[R03DA08, bamifylline, Valproic acid may increase the excretion rate of Bamifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Deutetrabenazine.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Beclamide.]
[N06BC01, caffeine, Valproic acid may increase the excretion rate of Caffeine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Oxybuprocaine.]
[J01XX08, linezolid, The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Valproic acid.]
[J05AF06, abacavir, The metabolism of Abacavir can be decreased when combined with Valproic acid.]
[J05AE09, tipranavir, The metabolism of Valproic acid can be increased when combined with Tipranavir.]
[L04AB02, infliximab, The metabolism of Valproic acid can be increased when combined with Infliximab.]
[L01EX10, midostaurin, The metabolism of Midostaurin can be decreased when combined with Valproic acid.]
[L01ED04, brigatinib, The metabolism of Brigatinib can be decreased when combined with Valproic acid.]
[N04BD03, safinamide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Safinamide.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Valproic acid.]
[L01BC06, capecitabine, The metabolism of Capecitabine can be decreased when combined with Valproic acid.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Valproic acid.]
[L01EH02, neratinib, The metabolism of Neratinib can be decreased when combined with Valproic acid.]
[L01XH01, vorinostat, The risk or severity of gastrointestinal bleeding and thrombocytopenia can be increased when Valproic acid is combined with Vorinostat.]
[L01EM02, copanlisib, The metabolism of Copanlisib can be decreased when combined with Valproic acid.]
[L01EF03, abemaciclib, The metabolism of Abemaciclib can be decreased when combined with Valproic acid.]
[J05AG03, efavirenz, The metabolism of Valproic acid can be increased when combined with Efavirenz.]
[N04AA11, bornaprine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[S01BC11, bromfenac, The protein binding of Valproic acid can be decreased when combined with Bromfenac.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Valproic acid is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Brotizolam.]
[M01AB07, bumadizone, The protein binding of Valproic acid can be decreased when combined with Bumadizone.]
[L01EL02, acalabrutinib, The metabolism of Acalabrutinib can be decreased when combined with Valproic acid.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Valproic acid is combined with Butobarbital.]
[J05AX18, letermovir, The excretion of Valproic acid can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Butriptyline is combined with Valproic acid.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Valproic acid.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Capsaicin.]
[A10BK04, ertugliflozin, The metabolism of Valproic acid can be decreased when combined with Ertugliflozin.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Valproic acid is combined with Vinylbital.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Valproic acid.]
[C09AA01, captopril, The excretion of Captopril can be decreased when combined with Valproic acid.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Macimorelin.]
[L02BB05, apalutamide, The serum concentration of Valproic acid can be increased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The serum concentration of carbamazepine-10,11­ epoxide (CBZ-E), an active metabolite of Carbamazepine, can be increased when used in combination with Valproic acid.]
[A03AA03, camylofine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Valproic acid.]
[C07AG02, carvedilol, The metabolism of Carvedilol can be decreased when combined with Valproic acid.]
[B02BX09, fostamatinib, The metabolism of Valproic acid can be decreased when combined with Fostamatinib.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Valproic acid.]
[B02BX08, avatrombopag, The excretion of Valproic acid can be decreased when combined with Avatrombopag.]
[L04AA37, baricitinib, The serum concentration of Baricitinib can be increased when it is combined with Valproic acid.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Encorafenib is combined with Valproic acid.]
[L01EE03, binimetinib, The metabolism of Binimetinib can be decreased when combined with Valproic acid.]
[J01DD14, ceftibuten, The excretion of Valproic acid can be decreased when combined with Ceftibuten.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Valproic acid.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Valproic acid.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Ivosidenib.]
[A16AX14, migalastat, The metabolism of Migalastat can be decreased when combined with Valproic acid.]
[N03AX17, stiripentol, The metabolism of Valproic acid can be decreased when combined with Stiripentol.]
[J05AX24, tecovirimat, The metabolism of Valproic acid can be decreased when combined with Tecovirimat.]
[L01EM04, duvelisib, The metabolism of Duvelisib can be decreased when combined with Valproic acid.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Valproic acid.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Valproic acid.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Valproic acid is combined with Carbromal.]
[A10BB06, carbutamide, The metabolism of Carbutamide can be decreased when combined with Valproic acid.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Chloroprocaine.]
[R06AA06, chlorphenoxamine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The protein binding of Valproic acid can be decreased when combined with Lornoxicam.]
[R03DA02, oxtriphylline, Valproic acid may increase the excretion rate of Oxtriphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Inotersen is combined with Valproic acid.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Valproic acid.]
[R03BB08, revefenacin, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L04AA39, emapalumab, The metabolism of Valproic acid can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The metabolism of Carmustine can be decreased when combined with Valproic acid.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Gilteritinib is combined with Valproic acid.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Amifampridine is combined with Valproic acid.]
[A06AX05, prucalopride, The metabolism of Prucalopride can be decreased when combined with Valproic acid.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Valproic acid.]
[B01AC23, cilostazol, The serum concentration of Cilostazol can be increased when it is combined with Valproic acid.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Valproic acid is combined with Cinitapride.]
[P02BX04, triclabendazole, The metabolism of Valproic acid can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Esketamine.]
[L04AA42, siponimod, The risk or severity of adverse effects can be increased when Valproic acid is combined with Siponimod.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation can be increased when Clarithromycin is combined with Valproic acid.]
[N06BA14, solriamfetol, The risk or severity of adverse effects can be increased when Valproic acid is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Brexanolone.]
[L01EN01, erdafitinib, The metabolism of Erdafitinib can be decreased when combined with Valproic acid.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Clobazam.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Cloxazolam.]
[C09CA06, candesartan, The metabolism of Candesartan can be decreased when combined with Valproic acid.]
[L04AB01, etanercept, The metabolism of Valproic acid can be increased when combined with Etanercept.]
[L01EM03, alpelisib, The serum concentration of Valproic acid can be decreased when it is combined with Alpelisib.]
[J01DC04, cefaclor, The excretion of Valproic acid can be decreased when combined with Cefaclor.]
[J01DB05, cefadroxil, The excretion of Valproic acid can be decreased when combined with Cefadroxil.]
[J01DC03, cefamandole, The excretion of Valproic acid can be decreased when combined with Cefamandole.]
[J01DB04, cefazolin, The excretion of Valproic acid can be decreased when combined with Cefazolin.]
[L02BB06, darolutamide, The metabolism of Darolutamide can be decreased when combined with Valproic acid.]
[L01EX15, pexidartinib, Valproic acid may increase the hepatotoxic activities of Pexidartinib.]
[J01DD12, cefoperazone, The excretion of Valproic acid can be decreased when combined with Cefoperazone.]
[J01DD01, cefotaxime, The excretion of Valproic acid can be decreased when combined with Cefotaxime.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Cyamemazine.]
[J01DC07, cefotiam, The excretion of Valproic acid can be decreased when combined with Cefotiam.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Cicletanine is combined with Valproic acid.]
[J01DD07, ceftizoxime, The excretion of Valproic acid can be decreased when combined with Ceftizoxime.]
[J01DD04, ceftriaxone, The excretion of Valproic acid can be decreased when combined with Ceftriaxone.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Valproic acid.]
[L01EJ02, fedratinib, The metabolism of Fedratinib can be decreased when combined with Valproic acid.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Entrectinib.]
[N07XX11, pitolisant, Valproic acid may increase the QTc-prolonging activities of Pitolisant.]
[J04AK08, pretomanid, The metabolism of Pretomanid can be decreased when combined with Valproic acid.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Valproic acid.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Valproic acid.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Yohimbine.]
[J01DB01, cephalexin, The excretion of Valproic acid can be decreased when combined with Cephalexin.]
[J01DB02, cephaloridine, The excretion of Valproic acid can be decreased when combined with Cefaloridine.]
[J01DB03, cephalothin, The excretion of Valproic acid can be decreased when combined with Cefalotin.]
[G03DB05, demegestone, The metabolism of Demegestone can be increased when combined with Valproic acid.]
[L01FD03, ado-trastuzumab emtansine, The metabolism of Trastuzumab emtansine can be decreased when combined with Valproic acid.]
[N02CC08, lasmiditan, The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Valproic acid.]
[L01EL03, zanubrutinib, The metabolism of Zanubrutinib can be decreased when combined with Valproic acid.]
[G03AC09, desogestrel, The metabolism of Desogestrel can be increased when combined with Valproic acid.]
[B06AX03, voxelotor, The serum concentration of Voxelotor can be increased when it is combined with Valproic acid.]
[N03AX25, cenobamate, The serum concentration of Valproic acid can be decreased when it is combined with Cenobamate.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Valproic acid.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Dexchlorpheniramine is combined with Valproic acid.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Dezocine.]
[L01EX18, avapritinib, The metabolism of Avapritinib can be decreased when combined with Valproic acid.]
[N05CM21, lemborexant, The serum concentration of Valproic acid can be decreased when it is combined with Lemborexant.]
[L01XX72, tazemetostat, The metabolism of Tazemetostat can be decreased when combined with Valproic acid.]
[N05AD10, lumateperone, The serum concentration of Lumateperone can be increased when it is combined with Valproic acid.]
[M01AX21, diacetylrhein, The metabolism of Valproic acid can be decreased when combined with Diacerein.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Valproic acid.]
[H02CA02, osilodrostat, The metabolism of Valproic acid can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Amprenavir can be decreased when combined with Valproic acid.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Valproic acid is combined with Frovatriptan.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Dichloralphenazone.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Valproic acid.]
[G03DB08, dienogest, The metabolism of Dienogest can be increased when combined with Valproic acid.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Valproic acid is combined with Difenoxin.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Valproic acid.]
[M01AH02, rofecoxib, The protein binding of Valproic acid can be decreased when combined with Rofecoxib.]
[L01XF03, bexarotene, Valproic acid may increase the Pseudotumor Cerebri activities of Bexarotene.]
[C08CA16, clevidipine, The metabolism of Valproic acid can be decreased when combined with Clevidipine.]
[C01BD07, dronedarone, Valproic acid may increase the QTc-prolonging activities of Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Valpromide.]
[L01AA02, chlorambucil, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Chlorambucil.]
[S03AA08, chloramphenicol, The metabolism of Valproic acid can be decreased when combined with Chloramphenicol.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Valproic acid.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Chlordiazepoxide.]
[L01FX17, sacituzumab govitecan, The serum concentration of Sacituzumab govitecan can be increased when it is combined with Valproic acid.]
[A03AA08, dihexyverine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[P01BE01, artemisinin, The metabolism of Artemisinin can be decreased when combined with Valproic acid.]
[G04BD09, trospium, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, The protein binding of Valproic acid can be decreased when combined with Droxicam.]
[M02AA27, dexketoprofen, The protein binding of Valproic acid can be decreased when combined with Dexketoprofen.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Valproic acid is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Chlormezanone.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Dyclonine.]
[C08CA17, levamlodipine, The serum concentration of Levamlodipine can be increased when it is combined with Valproic acid.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Ebastine is combined with Valproic acid.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Valproic acid.]
[P01BB01, proguanil, The metabolism of Proguanil can be decreased when combined with Valproic acid.]
[N05CD14, remimazolam, The risk or severity of sedation can be increased when Valproic acid is combined with Remimazolam.]
[L04AC19, satralizumab, The serum concentration of Valproic acid can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Valproic acid is combined with Oliceridine.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Valproic acid.]
[L01EX23, pralsetinib, The metabolism of Valproic acid can be decreased when combined with Pralsetinib.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Valproic acid.]
[N05AA01, chlorpromazine, The serum concentration of Valproic acid can be increased when it is combined with Chlorpromazine.]
[A10BB02, chlorpropamide, The metabolism of Chlorpropamide can be decreased when combined with Valproic acid.]
[N05AF03, chlorprothixene, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Chlorzoxazone.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Etifoxine.]
[N02BA07, ethenzamide, The protein binding of Valproic acid can be decreased when combined with Ethenzamide.]
[N02BA03, choline salicylate, The serum concentration of Valproic acid can be increased when it is combined with Choline salicylate.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Valproic acid is combined with Ethyl loflazepate.]
[G03DC06, ethynodiol, The metabolism of Etynodiol can be increased when combined with Valproic acid.]
[M01AB08, etodolac, The protein binding of Valproic acid can be decreased when combined with Etodolac.]
[M02AA06, etofenamate, The protein binding of Valproic acid can be decreased when combined with Etofenamate.]
[B06AC06, berotralstat, The risk or severity of QTc prolongation can be increased when Berotralstat is combined with Valproic acid.]
[A16AX20, lonafarnib, The metabolism of Lonafarnib can be decreased when combined with Valproic acid.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Valproic acid.]
[J05AJ04, cabotegravir, The excretion of Valproic acid can be decreased when combined with Cabotegravir.]
[P03AX07, abametapir, The serum concentration of Valproic acid can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The metabolism of Valproic acid can be decreased when combined with Tepotinib.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Valproic acid is combined with Febarbamate.]
[N03AX10, felbamate, The serum concentration of Valproic acid can be increased when it is combined with Felbamate.]
[M01AE05, fenbufen, The protein binding of Valproic acid can be decreased when combined with Fenbufen.]
[N06BA10, fenethylline, Valproic acid may increase the excretion rate of Fenethylline which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD15, cefdinir, The excretion of Cefdinir can be decreased when combined with Valproic acid.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Flumequine is combined with Valproic acid.]
[S01JA01, fluorescein, The excretion of Fluorescein can be decreased when combined with Valproic acid.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Valproic acid.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Valproic acid.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Valproic acid is combined with Trichloroethylene.]
[L03AB10, peginterferon alfa-2b, The metabolism of Valproic acid can be increased when combined with Peginterferon alfa-2b.]
[A02BA01, cimetidine, The excretion of Valproic acid can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Valproic acid is combined with Gabapentin.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Valproic acid.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Valproic acid.]
[L01EN03, infigratinib, The metabolism of Infigratinib can be decreased when combined with Valproic acid.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Valproic acid.]
[L01XA01, cisplatin, The metabolism of Valproic acid can be decreased when combined with Cisplatin.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Citalopram.]
[H01AC07, somapacitan, The metabolism of Valproic acid can be decreased when combined with Somapacitan.]
[C03DA05, finerenone, The serum concentration of Finerenone can be increased when it is combined with Valproic acid.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Valproic acid is combined with Fexinidazole.]
[L01XX74, belzutifan, The serum concentration of Belzutifan can be increased when it is combined with Valproic acid.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Mobocertinib.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Clemastine is combined with Valproic acid.]
[A10BB12, glimepiride, The metabolism of Glimepiride can be decreased when combined with Valproic acid.]
[A10BB08, gliquidone, The metabolism of Gliquidone can be decreased when combined with Valproic acid.]
[N06AX25, St. John's wort extract, The risk or severity of adverse effects can be increased when Valproic acid is combined with St. John's Wort.]
[L01EA06, asciminib, The metabolism of Valproic acid can be decreased when combined with Asciminib.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Valproic acid.]
[D11AH08, abrocitinib, The metabolism of Abrocitinib can be decreased when combined with Valproic acid.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Valproic acid.]
[C10AB01, clofibrate, The metabolism of Valproic acid can be decreased when combined with Clofibrate.]
[B06AX04, mitapivat, The metabolism of Valproic acid can be increased when combined with Mitapivat.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Pacritinib is combined with Valproic acid.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Valproic acid.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Clonazepam.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Valproic acid.]
[C01EB24, mavacamten, The serum concentration of Mavacamten can be increased when it is combined with Valproic acid.]
[J05AH02, oseltamivir, The excretion of Oseltamivir can be decreased when combined with Valproic acid.]
[A02BC08, vonoprazan, The metabolism of Valproic acid can be decreased when combined with Vonoprazan.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Clotiazepam.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Valproic acid.]
[M02AA08, felbinac, The protein binding of Valproic acid can be decreased when combined with Felbinac.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Granisetron is combined with Valproic acid.]
[N05AH02, clozapine, The risk or severity of QTc prolongation can be increased when Clozapine is combined with Valproic acid.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Halazepam.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Cocaine.]
[M09AX11, palovarotene, Valproic acid may increase the Pseudotumor Cerebri activities of Palovarotene.]
[C02KB01, metyrosine, Valproic acid may increase the sedative activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Valproic acid can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, The protein binding of Valproic acid can be decreased when combined with Proquazone.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Codeine.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Valproic acid is combined with Hexafluronium.]
[M04AC01, colchicine, The metabolism of Colchicine can be decreased when combined with Valproic acid.]
[A03AB10, hexocyclium, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[L04AA13, leflunomide, The metabolism of Leflunomide can be decreased when combined with Valproic acid.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Valproic acid.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Valproic acid is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Valproic acid is combined with Ifenprodil.]
[A10BX03, nateglinide, The metabolism of Nateglinide can be decreased when combined with Valproic acid.]
[N02BA16, imidazole-2-hydroxybenzoate, The protein binding of Valproic acid can be decreased when combined with Imidazole salicylate.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Telithromycin is combined with Valproic acid.]
[B01AC10, indobufen, The protein binding of Valproic acid can be decreased when combined with Indobufen.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Valproic acid.]
[J05AB14, valganciclovir, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Valganciclovir.]
[M01AH03, valdecoxib, The protein binding of Valproic acid can be decreased when combined with Valdecoxib.]
[A03AX10, isometheptene, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Isometheptene.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Valproic acid is combined with Almotriptan.]
[M01AH04, parecoxib, The protein binding of Valproic acid can be decreased when combined with Parecoxib.]
[J02AC02, itraconazole, The metabolism of Valproic acid can be decreased when combined with Itraconazole.]
[S01AD03, acyclovir, The excretion of Valproic acid can be decreased when combined with Acyclovir.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Emedastine is combined with Valproic acid.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Ketazolam.]
[M01AA06, kebuzone, The protein binding of Valproic acid can be decreased when combined with Kebuzone.]
[L02BA03, fulvestrant, The metabolism of Fulvestrant can be decreased when combined with Valproic acid.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Imatinib.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Valproic acid.]
[A02BC05, esomeprazole, The excretion of Valproic acid can be decreased when combined with Esomeprazole.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Valproic acid.]
[V03AF07, rasburicase, The risk or severity of methemoglobinemia can be increased when Rasburicase is combined with Valproic acid.]
[B03XA02, darbepoetin alfa, The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Valproic acid.]
[N03AX09, lamotrigine, Valproic acid may decrease the excretion rate of Lamotrigine which could result in a higher serum level.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Valproic acid.]
[N07BC04, lofexidine, The therapeutic efficacy of Valproic acid can be increased when used in combination with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Valproic acid.]
[M01AB09, lonazolac, The protein binding of Valproic acid can be decreased when combined with Lonazolac.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Lormetazepam.]
[H01AA02, cosyntropin, Tetracosactide may increase the hepatotoxic activities of Valproic acid.]
[M02AA31, loxoprofen, The protein binding of Valproic acid can be decreased when combined with Loxoprofen.]
[C08CA11, manidipine, The metabolism of Valproic acid can be decreased when combined with Manidipine.]
[A03AA04, mebeverine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Medifoxamine.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Valproic acid.]
[J01DH02, meropenem, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Meropenem.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Valproic acid.]
[R06AD04, methdilazine, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Methdilazine.]
[N04AA03, methixene, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[R03CB02, methoxyphenamine, The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Valproic acid.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Valproic acid is combined with Cyclobarbital.]
[S01BC10, nepafenac, The protein binding of Valproic acid can be decreased when combined with Nepafenac.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Melperone is combined with Valproic acid.]
[J05AF07, tenofovir disoproxil, The excretion of Tenofovir disoproxil can be decreased when combined with Valproic acid.]
[L01AA01, cyclophosphamide, The metabolism of Cyclophosphamide can be decreased when combined with Valproic acid.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Minaprine.]
[S01XA18, cyclosporine, The metabolism of Cyclosporine can be decreased when combined with Valproic acid.]
[N06AG02, moclobemide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Moclobemide.]
[N06BA07, modafinil, The metabolism of Valproic acid can be decreased when combined with Armodafinil.]
[R06AX02, cyproheptadine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Valproic acid.]
[C10AA07, rosuvastatin, The excretion of Valproic acid can be decreased when combined with Rosuvastatin.]
[M02AA02, mofebutazone, The protein binding of Valproic acid can be decreased when combined with Mofebutazone.]
[M01AX22, morniflumate, The protein binding of Valproic acid can be decreased when combined with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Conivaptan can be decreased when combined with Valproic acid.]
[J05AF10, entecavir, The metabolism of Entecavir can be decreased when combined with Valproic acid.]
[G04BE09, vardenafil, The metabolism of Vardenafil can be decreased when combined with Valproic acid.]
[M01AH05, etoricoxib, The protein binding of Valproic acid can be decreased when combined with Etoricoxib.]
[L01AX04, dacarbazine, The metabolism of Dacarbazine can be decreased when combined with Valproic acid.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Valproic acid is combined with Dantrolene.]
[J04BA02, dapsone, The risk or severity of methemoglobinemia can be increased when Dapsone is combined with Valproic acid.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Valproic acid is combined with Deanol.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Valproic acid.]
[M01AX01, nabumetone, The protein binding of Valproic acid can be decreased when combined with Nabumetone.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Nordazepam.]
[C07AB12, nebivolol, The metabolism of Nebivolol can be decreased when combined with Valproic acid.]
[N06AX06, nefazodone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Niaprazine.]
[L02BB02, nilutamide, The metabolism of Nilutamide can be decreased when combined with Valproic acid.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Tiagabine.]
[G03DB04, nomegestrol, The metabolism of Nomegestrol can be increased when combined with Valproic acid.]
[C01CA23, theodrenaline, Valproic acid may increase the excretion rate of Theodrenaline which could result in a lower serum level and potentially a reduction in efficacy.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Valproic acid is combined with Cisatracurium.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Escitalopram.]
[G04BD08, solifenacin, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[A07EC03, olsalazine, The serum concentration of Valproic acid can be increased when it is combined with Olsalazine.]
[N06AA01, desipramine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Desipramine.]
[J01DH03, ertapenem, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Ertapenem.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Valproic acid.]
[M01AE12, oxaprozin, The protein binding of Valproic acid can be decreased when combined with Oxaprozin.]
[N03AF02, oxcarbazepine, The serum concentration of the active metabolites of Oxcarbazepine can be decreased when Oxcarbazepine is used in combination with Valproic acid.]
[S03BA01, dexamethasone, The excretion of Dexamethasone can be decreased when combined with Valproic acid.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Oxiracetam.]
[N04AA08, dexetimide, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Dexfenfluramine can be decreased when combined with Valproic acid.]
[A03AA01, oxyphencyclimine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Valproic acid can be increased when combined with Adalimumab.]
[N06BA02, dextroamphetamine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Valproic acid.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Valproic acid is combined with Dextromethorphan.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Valproic acid is combined with Paramethadione.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Clopidogrel can be decreased when combined with Valproic acid.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Valproic acid is combined with Diamorphine.]
[C04AD01, pentifylline, Valproic acid may increase the excretion rate of Pentifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Diazepam.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Phenacemide.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Phenol.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Phensuximide.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Valproic acid is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Cinchocaine.]
[S01BC03, diclofenac, The protein binding of Valproic acid can be decreased when combined with Diclofenac.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Valproic acid.]
[A03AA07, dicyclomine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[J05AF03, zalcitabine, The excretion of Zalcitabine can be decreased when combined with Valproic acid.]
[J05AF02, didanosine, The excretion of Didanosine can be decreased when combined with Valproic acid.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Valproic acid.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Pipamperone.]
[A03AB14, pipenzolate, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01DC04, ixabepilone, The metabolism of Ixabepilone can be decreased when combined with Valproic acid.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Valproic acid.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Valproic acid is combined with Diethylpropion.]
[L02AA01, diethylstilbestrol, The metabolism of Diethylstilbestrol can be increased when combined with Valproic acid.]
[C08CA03, isradipine, The risk or severity of QTc prolongation can be increased when Isradipine is combined with Valproic acid.]
[A03AB11, poldine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, The serum concentration of Valproic acid can be increased when it is combined with Diflunisal.]
[C01AA04, digitoxin, The metabolism of Digitoxin can be decreased when combined with Valproic acid.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Valproic acid.]
[C02DB01, dihydralazine, The metabolism of Dihydralazine can be decreased when combined with Valproic acid.]
[C10AX09, ezetimibe, The metabolism of Ezetimibe can be decreased when combined with Valproic acid.]
[C04AE04, dihydroergocristine, The metabolism of Dihydroergocristine can be decreased when combined with Valproic acid.]
[N02CA01, dihydroergotamine, The metabolism of Dihydroergotamine can be decreased when combined with Valproic acid.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Hydromorphone.]
[J05AE08, atazanavir, The metabolism of Valproic acid can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Valproic acid.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Pramocaine.]
[C08DB01, diltiazem, The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Valproic acid.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Valproic acid.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Valproic acid is combined with Pridinol.]
[R06AB03, dimethindene, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[M02AX03, dimethyl sulfoxide, The metabolism of Valproic acid can be decreased when combined with Dimethyl sulfoxide.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Progabide.]
[N06BC02, propentofylline, Valproic acid may increase the excretion rate of Propentofylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N02BB04, propyphenazone, The protein binding of Valproic acid can be decreased when combined with Propyphenazone.]
[M01AB14, proglumetacin, The protein binding of Valproic acid can be decreased when combined with Proglumetacin.]
[G02AD02, dinoprostone, The excretion of Valproic acid can be decreased when combined with Dinoprostone.]
[C05CA03, diosmin, The metabolism of Valproic acid can be decreased when combined with Diosmin.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Proparacaine.]
[R03DA03, proxyphylline, Valproic acid may increase the excretion rate of Proxyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Valproic acid is combined with Diphenoxylate.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Quazepam.]
[C09AA06, quinapril, The excretion of Quinapril can be decreased when combined with Valproic acid.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Valproic acid is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Quinupramine.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Cisapride.]
[S01XA23, sirolimus, The metabolism of Sirolimus can be decreased when combined with Valproic acid.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Valproic acid is combined with Remoxipride.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Valproic acid.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Valproic acid.]
[S02AA12, rifamycin SV, The metabolism of Valproic acid can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Valproic acid can be increased when combined with Rifapentine.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Valproic acid is combined with Riluzole.]
[N05AX08, risperidone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Risperidone.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Valproic acid.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Ropivacaine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Valproic acid.]
[L01EX01, sunitinib, The metabolism of Sunitinib can be decreased when combined with Valproic acid.]
[C03XA01, tolvaptan, The metabolism of Tolvaptan can be decreased when combined with Valproic acid.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be decreased when combined with Valproic acid.]
[S01BC05, ketorolac, The protein binding of Valproic acid can be decreased when combined with Ketorolac.]
[C01EB18, ranolazine, The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Valproic acid.]
[N02BA06, salsalate, The protein binding of Valproic acid can be decreased when combined with Salsalate.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Valproic acid.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Domperidone.]
[N06AA16, dothiepin, The metabolism of Dosulepin can be decreased when combined with Valproic acid.]
[N06AA12, doxepin, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[L01DB01, doxorubicin, The metabolism of Doxorubicin can be decreased when combined with Valproic acid.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Valproic acid.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Valproic acid is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Valproic acid.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Valproic acid.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Sibutramine.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be decreased when combined with Valproic acid.]
[V03AG05, sodium phosphate, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Sodium phosphate, monobasic.]
[R03DA01, dyphylline, Valproic acid may increase the excretion rate of Dyphylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Sultopride is combined with Valproic acid.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Valproic acid is combined with Sumatriptan.]
[C07AB13, talinolol, The risk or severity of QTc prolongation can be increased when Talinolol is combined with Valproic acid.]
[J01CG02, tazobactam, The excretion of Valproic acid can be decreased when combined with Tazobactam.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Temafloxacin.]
[L01AX03, temozolomide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Temozolomide.]
[M01AC02, tenoxicam, The protein binding of Valproic acid can be decreased when combined with Tenoxicam.]
[D01BA02, terbinafine, The metabolism of Terbinafine can be decreased when combined with Valproic acid.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Terodiline.]
[A08AB01, orlistat, Orlistat can cause a decrease in the absorption of Valproic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Valproic acid is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Valproic acid is combined with Thiopropazate.]
[G04BD01, emepronium, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The metabolism of Tianeptine can be decreased when combined with Valproic acid.]
[C09AA02, enalapril, The excretion of Valproic acid can be decreased when combined with Enalapril.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Tofisopam.]
[M01AG02, tolfenamic acid, The protein binding of Valproic acid can be decreased when combined with Tolfenamic acid.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Toloxatone.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Valproic acid.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Valproic acid.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Toremifene.]
[C03CA04, torsemide, The metabolism of Torasemide can be decreased when combined with Valproic acid.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Valproic acid is combined with Chloral hydrate.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Valproic acid is combined with Triclofos.]
[A03AB08, tridihexethyl, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Trimethobenzamide.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Valproic acid.]
[N04AA12, tropatepine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Valproic acid.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Valproic acid is combined with Urapidil.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Valproic acid.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Valproic acid is combined with Veralipride.]
[L01CA04, vinorelbine, The metabolism of Vinorelbine can be decreased when combined with Valproic acid.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Epinastine is combined with Valproic acid.]
[N06AX16, venlafaxine, The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Venlafaxine.]
[S01EA01, epinephrine, The metabolism of Valproic acid can be decreased when combined with Epinephrine.]
[N05CF02, zolpidem, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, The protein binding of Valproic acid can be decreased when combined with Zomepirac.]
[N03AX15, zonisamide, The risk or severity of QTc prolongation can be increased when Zonisamide is combined with Valproic acid.]
[N05CF01, zopiclone, The metabolism of Zopiclone can be decreased when combined with Valproic acid.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Zotepine.]
[C02AC02, guanfacine, The serum concentration of Valproic acid can be increased when it is combined with Guanfacine.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Valproic acid.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Ergometrine.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Valproic acid is combined with Ergoloid mesylate.]
[N02CA02, ergotamine, The metabolism of Ergotamine can be decreased when combined with Valproic acid.]
[S01AA13, fusidic acid, The metabolism of Fusidic acid can be decreased when combined with Valproic acid.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Valproic acid.]
[N07XX04, sodium oxybate, The serum concentration of Sodium oxybate can be increased when it is combined with Valproic acid.]
[M01AG01, mefenamic acid, The protein binding of Valproic acid can be decreased when combined with Mefenamic acid.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Valproic acid.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Estazolam.]
[A02BC02, pantoprazole, The excretion of Valproic acid can be decreased when combined with Pantoprazole.]
[H05BX01, cinacalcet, The metabolism of Cinacalcet can be decreased when combined with Valproic acid.]
[G03CA03, estradiol, The metabolism of Estradiol can be increased when combined with Valproic acid.]
[G03CA57, estrogens, conjugated (USP), The excretion of Valproic acid can be decreased when combined with Conjugated estrogens.]
[J04AK02, ethambutol, The metabolism of Valproic acid can be decreased when combined with Ethambutol.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Valproic acid.]
[C01CA15, gepefrine, The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Gepefrine.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Valproic acid.]
[L02AA03, ethinyl estradiol, The metabolism of Ethinylestradiol can be increased when combined with Valproic acid.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Valproic acid.]
[N04AA05, profenamine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The serum concentration of Valproic acid can be decreased when it is combined with Ethosuximide.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Valproic acid is combined with Ethotoin.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Ethyl chloride.]
[M01AC06, meloxicam, The protein binding of Valproic acid can be decreased when combined with Meloxicam.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Ethylmorphine.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Etidocaine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Valproic acid.]
[L01CB01, etoposide, The metabolism of Etoposide can be decreased when combined with Valproic acid.]
[D05BB01, etretinate, Valproic acid may increase the Pseudotumor Cerebri activities of Etretinate.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Valproic acid is combined with Sertindole.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Valproic acid.]
[L04AD02, tacrolimus, The serum concentration of Tacrolimus can be increased when it is combined with Valproic acid.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Valproic acid.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Valproic acid.]
[R06AX12, terfenadine, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Terfenadine.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Valproic acid is combined with Bupropion.]
[N06AB08, fluvoxamine, The metabolism of Valproic acid can be decreased when combined with Fluvoxamine.]
[C01BB03, tocainide, The metabolism of Tocainide can be decreased when combined with Valproic acid.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Encainide is combined with Valproic acid.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Valproic acid.]
[C10AA03, pravastatin, The excretion of Valproic acid can be decreased when combined with Pravastatin.]
[M01CB01, gold sodium thiomalate, The metabolism of Valproic acid can be decreased when combined with Sodium aurothiomalate.]
[A02BA03, famotidine, The excretion of Valproic acid can be decreased when combined with Famotidine.]
[A16AA01, levocarnitine, The excretion of Levocarnitine can be decreased when combined with Valproic acid.]
[P02CA03, albendazole, The metabolism of Albendazole can be decreased when combined with Valproic acid.]
[C08CA02, felodipine, The risk or severity of QTc prolongation can be increased when Felodipine is combined with Valproic acid.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Fendiline is combined with Valproic acid.]
[N03AX26, fenfluramine, The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Fenfluramine.]
[M01AE04, fenoprofen, The protein binding of Valproic acid can be decreased when combined with Fenoprofen.]
[N02AB03, fentanyl, The metabolism of Fentanyl can be decreased when combined with Valproic acid.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Valproic acid.]
[L01BB06, clofarabine, The excretion of Clofarabine can be decreased when combined with Valproic acid.]
[G04BD02, flavoxate, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Flecainide is combined with Valproic acid.]
[N02BG04, floctafenine, The protein binding of Valproic acid can be decreased when combined with Floctafenine.]
[J02AC01, fluconazole, The metabolism of Valproic acid can be decreased when combined with Fluconazole.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Flunarizine.]
[N05CD03, flunitrazepam, The metabolism of Valproic acid can be decreased when combined with Flunitrazepam.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Valproic acid is combined with Melitracen.]
[V03AZ01, ethanol, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC09, floxuridine, The metabolism of Valproic acid can be decreased when combined with Floxuridine.]
[L01BC02, fluorouracil, The metabolism of Fluorouracil can be decreased when combined with Valproic acid.]
[N06AB03, fluoxetine, The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Fluoxetine.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Fluphenazine.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Flurazepam.]
[S01BC04, flurbiprofen, The protein binding of Valproic acid can be decreased when combined with Flurbiprofen.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Fluspirilene is combined with Valproic acid.]
[L02BB01, flutamide, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Flutamide.]
[V04CX02, folic acid, The serum concentration of Folic acid can be decreased when it is combined with Valproic acid.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Valproic acid.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Valproic acid is combined with Alcuronium.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Furazolidone.]
[C03CA01, furosemide, The excretion of Valproic acid can be decreased when combined with Furosemide.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Valproic acid is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Valproic acid.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Valproic acid.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Gallamine.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Gallopamil is combined with Valproic acid.]
[S01AD09, ganciclovir, The excretion of Valproic acid can be decreased when combined with Ganciclovir.]
[N03AA04, barbexaclone, The serum concentration of Barbexaclone can be increased when it is combined with Valproic acid.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Valproic acid is combined with Bifemelane.]
[C10AB04, gemfibrozil, The metabolism of Valproic acid can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Telavancin is combined with Valproic acid.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Valproic acid.]
[L01EA02, dasatinib, The metabolism of Dasatinib can be decreased when combined with Valproic acid.]
[N04BC06, cabergoline, The metabolism of Cabergoline can be decreased when combined with Valproic acid.]
[C01CA21, cafedrine, Valproic acid may increase the excretion rate of Cafedrine which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AG04, etravirine, The metabolism of Etravirine can be decreased when combined with Valproic acid.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Valproic acid.]
[G03XA02, gestrinone, The metabolism of Gestrinone can be increased when combined with Valproic acid.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Valproic acid is combined with Alfentanil.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Valproic acid.]
[A10BB01, glyburide, The metabolism of Glyburide can be decreased when combined with Valproic acid.]
[A10BB09, gliclazide, The metabolism of Gliclazide can be decreased when combined with Valproic acid.]
[A10BB07, glipizide, The metabolism of Glipizide can be decreased when combined with Valproic acid.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Dexmedetomidine.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Glutethimide.]
[C05AE01, nitroglycerin, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Nitroglycerin.]
[C01BD04, dofetilide, The metabolism of Dofetilide can be decreased when combined with Valproic acid.]
[C02CA04, doxazosin, The metabolism of Doxazosin can be decreased when combined with Valproic acid.]
[L01EX02, sorafenib, The metabolism of Sorafenib can be decreased when combined with Valproic acid.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Valproic acid.]
[B01AA12, fluindione, The metabolism of Fluindione can be decreased when combined with Valproic acid.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Goserelin is combined with Valproic acid.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Haloperidol.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Valproic acid is combined with Halothane.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Valproic acid.]
[N05AH04, quetiapine, The risk or severity of QTc prolongation can be increased when Quetiapine is combined with Valproic acid.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Valproic acid is combined with Iprazochrome.]
[L01CE02, irinotecan, The risk or severity of neutropenia can be increased when Valproic acid is combined with Irinotecan.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Valproic acid is combined with Allobarbital.]
[M04AA01, allopurinol, The excretion of Allopurinol can be decreased when combined with Valproic acid.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Valproic acid.]
[G03DC01, allylestrenol, The metabolism of Allylestrenol can be decreased when combined with Valproic acid.]
[A07EC02, mesalamine, The serum concentration of Valproic acid can be increased when it is combined with Mesalazine.]
[N05CA16, hexobarbital, The serum concentration of Hexobarbital can be increased when it is combined with Valproic acid.]
[J05AG01, nevirapine, The metabolism of Valproic acid can be increased when combined with Nevirapine.]
[C08CA10, nilvadipine, The risk or severity of QTc prolongation can be increased when Nilvadipine is combined with Valproic acid.]
[M02AA26, nimesulide, The protein binding of Valproic acid can be decreased when combined with Nimesulide.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Oxatomide is combined with Valproic acid.]
[C03AA03, hydrochlorothiazide, The excretion of Hydrochlorothiazide can be decreased when combined with Valproic acid.]
[R05DA03, hydrocodone, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[S02BA01, hydrocortisone, The excretion of Hydrocortisone can be decreased when combined with Valproic acid.]
[G04BD06, propiverine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[P01BA02, hydroxychloroquine, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Hydroxychloroquine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Valproic acid is combined with Prothipendyl.]
[L01XX05, hydroxyurea, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Hydroxyurea.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Hydroxyzine.]
[J04AB04, rifabutin, The metabolism of Valproic acid can be increased when combined with Rifabutin.]
[R02AX02, ibuprofen, The protein binding of Valproic acid can be decreased when combined with Ibuprofen.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Valproic acid.]
[L01AA06, ifosfamide, The metabolism of Ifosfamide can be decreased when combined with Valproic acid.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Valproic acid is combined with Sufentanil.]
[N06AA02, imipramine, The risk or severity of QTc prolongation can be increased when Imipramine is combined with Valproic acid.]
[L01CD01, paclitaxel, The metabolism of Paclitaxel can be decreased when combined with Valproic acid.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Terlipressin is combined with Valproic acid.]
[M03BX02, tizanidine, The metabolism of Tizanidine can be decreased when combined with Valproic acid.]
[L01CE01, topotecan, Valproic acid may increase the excretion rate of Topotecan which could result in a lower serum level and potentially a reduction in efficacy.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Valproic acid.]
[S01BC01, indomethacin, The protein binding of Valproic acid can be decreased when combined with Indomethacin.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Valproic acid is combined with Milnacipran.]
[A03AA30, piperidolate, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Articaine.]
[A10BH01, sitagliptin, The excretion of Sitagliptin can be decreased when combined with Valproic acid.]
[V08AB02, iohexol, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Iohexol.]
[N05BA12, alprazolam, The metabolism of Alprazolam can be decreased when combined with Valproic acid.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Valproic acid is combined with Ramelteon.]
[R06AE01, buclizine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[C10AA06, cerivastatin, The metabolism of Cerivastatin can be decreased when combined with Valproic acid.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Valproic acid.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Valproic acid is combined with Alprenolol.]
[J05AF04, stavudine, The excretion of Stavudine can be decreased when combined with Valproic acid.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Valproic acid is combined with Iprindole.]
[G04BE01, alprostadil, The excretion of Alprostadil can be decreased when combined with Valproic acid.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Iproniazid.]
[J05AB13, penciclovir, The metabolism of Penciclovir can be decreased when combined with Valproic acid.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Isocarboxazid.]
[P01AX06, atovaquone, The metabolism of Valproic acid can be decreased when combined with Atovaquone.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Valproic acid.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Entacapone.]
[J04AC01, isoniazid, The metabolism of Valproic acid can be decreased when combined with Isoniazid.]
[C05AE02, isosorbide dinitrate, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Isosorbide dinitrate.]
[D10BA01, isotretinoin, Valproic acid may increase the Pseudotumor Cerebri activities of Isotretinoin.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Valproic acid.]
[L04AC07, tocilizumab, The metabolism of Valproic acid can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Valproic acid is combined with Ketanserin.]
[B01AC22, prasugrel, The metabolism of Prasugrel can be decreased when combined with Valproic acid.]
[J02AB02, ketoconazole, The metabolism of Valproic acid can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, The serum concentration of Olanzapine can be decreased when it is combined with Valproic acid.]
[M02AA10, ketoprofen, The protein binding of Valproic acid can be decreased when combined with Ketoprofen.]
[V03AC03, deferasirox, The metabolism of Valproic acid can be decreased when combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Valproic acid can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Mizolastine is combined with Valproic acid.]
[N04BC09, rotigotine, Valproic acid may increase the sedative activities of Rotigotine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Valproic acid.]
[C07AG01, labetalol, The metabolism of Labetalol can be decreased when combined with Valproic acid.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Valproic acid.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Lacosamide.]
[G03AD01, levonorgestrel, The metabolism of Levonorgestrel can be increased when combined with Valproic acid.]
[N04BA01, levodopa, The risk or severity of adverse effects can be increased when Valproic acid is combined with Levodopa.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Valproic acid.]
[N06BA13, armodafinil, The metabolism of Valproic acid can be decreased when combined with Armodafinil.]
[D06AX13, retapamulin, The metabolism of Retapamulin can be decreased when combined with Valproic acid.]
[N02CA07, lisuride, The risk or severity of adverse effects can be increased when Valproic acid is combined with Lisuride.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Lofepramine.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Loperamide is combined with Valproic acid.]
[N05BA06, lorazepam, The serum concentration of Lorazepam can be increased when it is combined with Valproic acid.]
[C10AA02, lovastatin, The metabolism of Lovastatin can be decreased when combined with Valproic acid.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Loxapine.]
[G03DC03, lynestrenol, The metabolism of Lynestrenol can be increased when combined with Valproic acid.]
[L01EG01, temsirolimus, The metabolism of Temsirolimus can be decreased when combined with Valproic acid.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Valproic acid can be increased when used in combination with Magnesium sulfate.]
[L01EA03, nilotinib, The metabolism of Nilotinib can be decreased when combined with Valproic acid.]
[N06AA21, maprotiline, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Valproic acid is combined with Mazindol.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Meclizine.]
[M02AA18, meclofenamic acid, The protein binding of Valproic acid can be decreased when combined with Meclofenamic acid.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Medazepam.]
[P01BC02, mefloquine, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Mefloquine.]
[N05CH01, melatonin, The excretion of Valproic acid can be decreased when combined with Melatonin.]
[N06DX01, memantine, The metabolism of Valproic acid can be decreased when combined with Memantine.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Meperidine.]
[C01CA11, mephentermine, The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Mephentermine.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Valproic acid is combined with Mephenytoin.]
[N03AA01, mephobarbital, The serum concentration of Phenobarbital, an active metabolite of Methylphenobarbital, can be increased when used in combination with Valproic acid.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Mepivacaine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Valproic acid is combined with Meprobamate.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Valproic acid is combined with Meptazinol.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Valproic acid.]
[N05AX13, paliperidone, The serum concentration of Paliperidone can be increased when it is combined with Valproic acid.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Valproic acid.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Valproic acid.]
[N06BA03, methamphetamine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Metamfetamine.]
[A03AB07, methantheline, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Valproic acid is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Methaqualone.]
[J05AF05, lamivudine, The excretion of Lamivudine can be decreased when combined with Valproic acid.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Valproic acid is combined with Metharbital.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Valproic acid is combined with Metergoline.]
[H03BB02, methimazole, The metabolism of Valproic acid can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Valproic acid may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Valproic acid is combined with Methocarbamol.]
[N05CA15, methohexital, The serum concentration of Methohexital can be increased when it is combined with Valproic acid.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Valproic acid is combined with Ziconotide.]
[L04AX03, methotrexate, The metabolism of Methotrexate can be decreased when combined with Valproic acid.]
[N05AA02, methotrimeprazine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[D05BA02, methoxsalen, The metabolism of Valproic acid can be decreased when combined with Methoxsalen.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Valproic acid is combined with Methoxyflurane.]
[V04CG05, methylene blue, Valproic acid may increase the serotonergic activities of Methylene blue.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Valproic acid.]
[N06BA04, methylphenidate, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Methylphenidate.]
[N03AF03, rufinamide, The serum concentration of Rufinamide can be increased when it is combined with Valproic acid.]
[G03EK01, methyltestosterone, The excretion of Valproic acid can be increased when combined with Methyltestosterone.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Valproic acid is combined with Methyprylon.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Valproic acid.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Valproic acid.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Valproic acid.]
[V04CD01, metyrapone, The metabolism of Valproic acid can be decreased when combined with Metyrapone.]
[C01BB02, mexiletine, The metabolism of Mexiletine can be decreased when combined with Valproic acid.]
[N06AX03, mianserin, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Mianserin.]
[S02AA13, miconazole, The metabolism of Valproic acid can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The protein binding of Valproic acid can be decreased when combined with Aminophenazone.]
[N05CD08, midazolam, The serum concentration of Midazolam can be increased when it is combined with Valproic acid.]
[G03XB01, mifepristone, The metabolism of Mifepristone can be increased when combined with Valproic acid.]
[C09CA03, valsartan, The metabolism of Valsartan can be decreased when combined with Valproic acid.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Valproic acid.]
[D11AX01, minoxidil, The metabolism of Minoxidil can be decreased when combined with Valproic acid.]
[N06BA12, lisdexamfetamine, The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Lisdexamfetamine.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Molindone.]
[C01BD01, amiodarone, The metabolism of Amiodarone can be decreased when combined with Valproic acid.]
[N06AA09, amitriptyline, The metabolism of Valproic acid can be decreased when combined with Amitriptyline.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Valproic acid.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Valproic acid is combined with Palonosetron.]
[L04AB05, certolizumab pegol, The metabolism of Valproic acid can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Valproic acid can be decreased when combined with Eltrombopag.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Valproic acid.]
[L04AA06, mycophenolic acid, The metabolism of Mycophenolic acid can be decreased when combined with Valproic acid.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Valproic acid is combined with Vecuronium.]
[N05CA02, amobarbital, The serum concentration of Amobarbital can be increased when it is combined with Valproic acid.]
[J05AJ01, raltegravir, The metabolism of Raltegravir can be decreased when combined with Valproic acid.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Valproic acid.]
[G03XC01, raloxifene, The metabolism of Valproic acid can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.]
[N03AB05, fosphenytoin, The serum concentration of Fosphenytoin can be decreased when it is combined with Valproic acid.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Valproic acid is combined with Ropinirole.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Valproic acid is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Nalbuphine.]
[V03AB15, naloxone, The metabolism of Naloxone can be decreased when combined with Valproic acid.]
[N07BB04, naltrexone, The metabolism of Naltrexone can be decreased when combined with Valproic acid.]
[L04AC03, anakinra, The metabolism of Valproic acid can be increased when combined with Anakinra.]
[N06BA01, amphetamine, The risk or severity of serotonin syndrome can be increased when Amphetamine is combined with Valproic acid.]
[M02AA12, naproxen, The protein binding of Valproic acid can be decreased when combined with Naproxen.]
[A10BG01, troglitazone, The metabolism of Valproic acid can be decreased when combined with Troglitazone.]
[N06AX21, duloxetine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Tolcapone.]
[B03XA03, methoxy polyethylene glycol-epoetin beta, The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Valproic acid.]
[L01CD02, docetaxel, The metabolism of Docetaxel can be decreased when combined with Valproic acid.]
[L02BG04, letrozole, The metabolism of Valproic acid can be decreased when combined with Letrozole.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Valproic acid is combined with Remifentanil.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Valproic acid.]
[N05AX14, iloperidone, The metabolism of Iloperidone can be decreased when combined with Valproic acid.]
[J02AA01, amphotericin B, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Amphotericin B.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Desvenlafaxine.]
[C09CA07, telmisartan, The metabolism of Valproic acid can be decreased when combined with Telmisartan.]
[J05AB11, valacyclovir, The excretion of Valaciclovir can be decreased when combined with Valproic acid.]
[M04AA03, febuxostat, The metabolism of Febuxostat can be decreased when combined with Valproic acid.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Nialamide.]
[C08CA04, nicardipine, The metabolism of Valproic acid can be decreased when combined with Nicardipine.]
[P02DA01, niclosamide, The metabolism of Niclosamide can be decreased when combined with Valproic acid.]
[N07BA01, nicotine, The metabolism of Valproic acid can be decreased when combined with Nicotine.]
[C08CA05, nifedipine, Valproic acid may increase the hypotensive activities of Nifedipine.]
[M02AA17, niflumic acid, The protein binding of Valproic acid can be decreased when combined with Niflumic acid.]
[V03AB22, amyl nitrite, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Amyl Nitrite.]
[C08CA06, nimodipine, Nimodipine can cause an increase in the absorption of Valproic acid resulting in an increased serum concentration and potentially a worsening of adverse effects.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Nitrazepam.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Valproic acid.]
[R07AX01, nitric oxide, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Nitric Oxide.]
[J01XE01, nitrofurantoin, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Nitrofurantoin.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Valproic acid is combined with Zaleplon.]
[N04BC05, pramipexole, Valproic acid may increase the sedative activities of Pramipexole.]
[C02DD01, nitroprusside, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Nitroprusside.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Nomifensine.]
[G03DC02, norethindrone, The metabolism of Norethisterone can be increased when combined with Valproic acid.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Valproic acid.]
[G03AC07, norgestrienone, The metabolism of Norgestrienone can be increased when combined with Valproic acid.]
[C02KX01, bosentan, The metabolism of Bosentan can be decreased when combined with Valproic acid.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Valproic acid.]
[R05DA07, noscapine, The metabolism of Valproic acid can be decreased when combined with Noscapine.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Valproic acid.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Ofloxacin is combined with Valproic acid.]
[L04AC04, rilonacept, The metabolism of Valproic acid can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Omeprazole can be decreased when combined with Valproic acid.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Valproic acid is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Valproic acid is combined with Opium.]
[C01AC01, ouabain, The excretion of Valproic acid can be decreased when combined with Ouabain.]
[A14AA08, oxandrolone, The metabolism of Valproic acid can be decreased when combined with Oxandrolone.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Oxazepam.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Valproic acid.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Valproic acid is combined with Oxprenolol.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Oxycodone.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Valproic acid is combined with Oxymorphone.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Oxypertine.]
[S01BC02, oxyphenbutazone, The protein binding of Valproic acid can be decreased when combined with Oxyphenbutazone.]
[A03AB03, oxyphenonium, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[S01AA04, oxytetracycline, The excretion of Valproic acid can be decreased when combined with Oxytetracycline.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Valproic acid.]
[V04CH30, 4-aminohippuric acid, The excretion of Valproic acid can be decreased when combined with Aminohippuric acid.]
[J04AA01, aminosalicylic acid, The serum concentration of Valproic acid can be increased when it is combined with Aminosalicylic acid.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Asenapine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Valproic acid.]
[M03AC01, pancuronium, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[G03DB06, chlormadinone, The metabolism of Chlormadinone can be increased when combined with Valproic acid.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Valproic acid.]
[N05CC05, paraldehyde, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Valproic acid is combined with Pargyline.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Valproic acid.]
[G04BD11, fesoterodine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Valproic acid is combined with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Penfluridol is combined with Valproic acid.]
[S01AA14, penicillin G, The excretion of Valproic acid can be decreased when combined with Benzylpenicillin.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Pentazocine.]
[N05CA01, pentobarbital, The serum concentration of Pentobarbital can be increased when it is combined with Valproic acid.]
[C04AD03, pentoxifylline, Valproic acid may increase the excretion rate of Pentoxifylline which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Perazine.]
[N04BC02, pergolide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Pergolide.]
[C08EX02, perhexiline, The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Valproic acid.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Perphenazine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Valproic acid.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Phenazocine.]
[G04BX06, phenazopyridine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Phenazopyridine.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Phenelzine.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Valproic acid.]
[N03AA02, phenobarbital, The serum concentration of Phenobarbital, an active metabolite of Phenobarbital, can be increased when used in combination with Valproic acid.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Phenoperidine.]
[B01AA04, phenprocoumon, The metabolism of Phenprocoumon can be decreased when combined with Valproic acid.]
[A08AA01, phentermine, The risk or severity of serotonin syndrome can be increased when Phentermine is combined with Valproic acid.]
[M02AA01, phenylbutazone, The protein binding of Valproic acid can be decreased when combined with Phenylbutazone.]
[A02BC06, dexlansoprazole, The metabolism of Dexlansoprazole can be decreased when combined with Valproic acid.]
[R01BA01, phenylpropanolamine, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Phenylpropanolamine.]
[N03AB02, phenytoin, The serum concentration of Phenytoin can be decreased when it is combined with Valproic acid.]
[L01XF02, alitretinoin, Valproic acid may increase the Pseudotumor Cerebri activities of Alitretinoin.]
[L04AB06, golimumab, The metabolism of Valproic acid can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Valproic acid.]
[N07BB03, acamprosate, The excretion of Acamprosate can be decreased when combined with Valproic acid.]
[L02BB03, bicalutamide, The metabolism of Bicalutamide can be decreased when combined with Valproic acid.]
[J05AB12, cidofovir, The excretion of Cidofovir can be decreased when combined with Valproic acid.]
[C08CX01, mibefradil, The risk or severity of QTc prolongation can be increased when Mibefradil is combined with Valproic acid.]
[S01EB01, pilocarpine, The metabolism of Valproic acid can be decreased when combined with Pilocarpine.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Valproic acid.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Valproic acid is combined with Pindolol.]
[C10AA05, atorvastatin, The metabolism of Atorvastatin can be decreased when combined with Valproic acid.]
[J01CA12, piperacillin, The excretion of Piperacillin can be decreased when combined with Valproic acid.]
[J05AE01, saquinavir, The risk or severity of QTc prolongation can be increased when Saquinavir is combined with Valproic acid.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Pipotiazine.]
[A02BX03, pirenzepine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Valproic acid is combined with Piritramide.]
[S01BC06, piroxicam, The protein binding of Valproic acid can be decreased when combined with Piroxicam.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Grepafloxacin.]
[N02CX01, pizotyline, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[J05AG02, delavirdine, The metabolism of Valproic acid can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Irbesartan can be decreased when combined with Valproic acid.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Valproic acid is combined with Proxibarbal.]
[D05AX05, tazarotene, Valproic acid may increase the Pseudotumor Cerebri activities of Tazarotene.]
[A10BG02, rosiglitazone, The metabolism of Rosiglitazone can be decreased when combined with Valproic acid.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Valproic acid is combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Valproic acid can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The excretion of Polythiazide can be decreased when combined with Valproic acid.]
[J05AE03, ritonavir, The metabolism of Valproic acid can be increased when combined with Ritonavir.]
[A10BH03, saxagliptin, The excretion of Saxagliptin can be decreased when combined with Valproic acid.]
[C10AA08, pitavastatin, The metabolism of Pitavastatin can be decreased when combined with Valproic acid.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Valproic acid.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Valproic acid is combined with Prazepam.]
[P02BA01, praziquantel, The metabolism of Praziquantel can be decreased when combined with Valproic acid.]
[H02AB07, prednisone, The metabolism of Valproic acid can be increased when combined with Prednisone.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Antazoline is combined with Valproic acid.]
[M02AA16, feprazone, The protein binding of Valproic acid can be decreased when combined with Feprazone.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Prenylamine is combined with Valproic acid.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Prilocaine.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Primaquine is combined with Valproic acid.]
[N03AA03, primidone, The serum concentration of Phenobarbital, an active metabolite of Primidone, can be increased when used in combination with Valproic acid.]
[M04AB01, probenecid, The metabolism of Valproic acid can be decreased when combined with Probenecid.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Probucol is combined with Valproic acid.]
[C01BA02, procainamide, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Procainamide.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Procaine.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Procarbazine.]
[C10AB05, fenofibrate, The metabolism of Fenofibrate can be decreased when combined with Valproic acid.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Valproic acid.]
[N04AA04, procyclidine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, The metabolism of Progesterone can be increased when combined with Valproic acid.]
[N05AA03, promazine, The risk or severity of QTc prolongation can be increased when Promazine is combined with Valproic acid.]
[R06AD02, promethazine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[C01BC03, propafenone, The risk or severity of QTc prolongation can be increased when Propafenone is combined with Valproic acid.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Propanidid.]
[A03AB05, propantheline, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[R06AX26, fexofenadine, The excretion of Fexofenadine can be decreased when combined with Valproic acid.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Periciazine.]
[N05CM06, propiomazine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[L01XH02, romidepsin, The metabolism of Romidepsin can be decreased when combined with Valproic acid.]
[N01AX10, propofol, The serum concentration of Propofol can be increased when it is combined with Valproic acid.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Valproic acid is combined with Dextropropoxyphene.]
[C07AA05, propranolol, The serum concentration of Propranolol can be increased when it is combined with Valproic acid.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Valproic acid is combined with Rizatriptan.]
[R03DC03, montelukast, The metabolism of Montelukast can be decreased when combined with Valproic acid.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Valproic acid.]
[R01BA02, pseudoephedrine, The risk or severity of serotonin syndrome can be increased when Valproic acid is combined with Pseudoephedrine.]
[N05AX12, aripiprazole, The metabolism of Aripiprazole can be decreased when combined with Valproic acid.]
[A03AB15, diphemanil, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Valproic acid.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Valproic acid is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Valproic acid is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Valproic acid is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Valproic acid is combined with Pyrantel.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Valproic acid.]
[C01BA01, quinidine, The metabolism of Quinidine can be decreased when combined with Valproic acid.]
[P01BC01, quinine, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Quinine.]
[A02BA02, ranitidine, The excretion of Ranitidine can be decreased when combined with Valproic acid.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Valproic acid.]
[J04AB02, rifampin, The metabolism of Valproic acid can be increased when combined with Rifampicin.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Valproic acid is combined with Oxitriptan.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Valproic acid.]
[N02BA05, salicylamide, The protein binding of Valproic acid can be decreased when combined with Salicylamide.]
[A07EC01, sulfasalazine, The serum concentration of Valproic acid can be increased when it is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The serum concentration of Valproic acid can be increased when it is combined with Salicylic acid.]
[S01FA02, scopolamine, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, The serum concentration of Secobarbital can be increased when it is combined with Valproic acid.]
[N04BD01, selegiline, The risk or severity of adverse effects can be increased when Valproic acid is combined with Selegiline.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Valproic acid is combined with Sotalol.]
[L01CD04, cabazitaxel, The metabolism of Cabazitaxel can be decreased when combined with Valproic acid.]
[A05AA01, chenodeoxycholic acid, The metabolism of Valproic acid can be decreased when combined with Chenodeoxycholic acid.]
[C01DA14, isosorbide mononitrate, The risk or severity of methemoglobinemia can be increased when Valproic acid is combined with Isosorbide mononitrate.]
[H02CA04, levoketoconazole, The metabolism of Valproic acid can be decreased when combined with Levoketoconazole.]
[M01AE11, tiaprofenic acid, The protein binding of Valproic acid can be decreased when combined with Tiaprofenic acid.]
[D11AX02, gamma-linolenic acid, The therapeutic efficacy of Valproic acid can be decreased when used in combination with Gamolenic acid.]
[R03BB01, ipratropium bromide, Valproic acid may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
